The parents of a 12-year-old boy who's on life support are appealing the decision of the UK Royal Courts of Justice to remove his oxygen and other life-sustaining treatment. They're taking their case to a Court of Appeal hearing in London on Wednesday.

As CBN News reported earlier this month, Family Division of the High Court Judge Emma Arbuthnot ruled "on the balance of probabilities" Archie Battersbee had already died after doctors told the court "it was highly likely" he was "brain stem dead."

Archie's mother and father, Holly Dance and Paul Battersbee are trying to give their son every chance at life after he was found unconscious on April 7 with a cord around his neck. He reportedly had participated in what is believed to be an online blackout challenge, according to watchdog Christian Concern.

The boy has remained on life support at the Royal London Hospital and has not regained consciousness.

Judge Arbuthnot ordered, "Medical professionals at the Royal London Hospital (1) to cease to ventilate mechanically Archie Battersbee; (2) to extubate Archie Battersbee; (3) to cease the administration of medication to Archie Battersbee, and (4) not to attempt any cardio or pulmonary resuscitation on Archie Battersbee when cardiac output ceases or respiratory effort ceases."

"The steps I have set out above are lawful," the judge contended. But she also gave Archie's mother and father, Holly Dance and Paul Battersbee permission to appeal her ruling.

Arbuthnot said there was a "compelling reason" why appeal judges should consider the case, according to ITV News.

According to Christian Concern, this is believed to be the first time that someone in the UK has been declared 'likely' to be dead based on an MRI test.

At a High Court hearing about Archie's case on June 20, Christian Legal Centre attorney Edward Devereux QC argued that evidence should instead show 'beyond reasonable doubt', as in criminal proceedings, that Archie is dead, rather than using a balance of probabilities test.

Archie's parents have been fighting a legal battle to give their son more time and to allow him to have more medical tests to assess whether his condition improves before making the decision about withdrawing his life support.

In a statement, Archie's mother, Hollie, and sister-in-law, Ella Carter, asked: "If Archie can be pronounced dead via an MRI, which is outside the bounds of the law, then what's going to be next?"

They also thanked everyone for the support the family has received from around the world.

"Archie's words, if he was sitting next to me right now, would be 'it melts my heart' and I'll use those words now, because everyone's support does melt my heart. So, thank you and please continue to support us in this fight," the statement said.

Proof of Life?

Archie's parents say a video of him gripping his mother's fingers is proof that he's still alive and his brain is functioning.

But his doctors believe there's no hope for the boy to recover since they believe his brain stem is dead. Scans reportedly show blood is not flowing to the area, according to Sky News. The stem lies at the base of the brain above the spinal cord. It is responsible for regulating most of the body's automatic functions essential for life. Doctors previously said Archie's stem is 50% damaged and that 10% to 20% of the stem is in necrosis where cells have died and/or are decaying.

***Please sign up forCBN Newslettersand download theCBN News appto ensure you keep receiving the latest news from a distinctly Christian perspective.***

Lawyers for the Barts Health NHS Trust said that doctors have repeatedly recreated the moment of the boy holding a clinician's hand, but the hospital workers said it was just "friction" not a grip, which the doctors say is consistent with muscle stiffness.

Eminent Pediatric Neurologist Testified About Cases of Persons Diagnosed as 'Brain Dead' Who Later Recovered

Dr. D. Alan Shewmon, M.D., professor emeritus of Neurology and Pediatrics at the University of California, gave expert testimony about numerous documented cases where persons diagnosed as 'brain dead' subsequently recovered.

When asked whether there was sufficient evidence for a reliable diagnosis of death in Archie's case, Shewmon replied, "Absolutely not."

An online petition to the hospital's chief executive officer has been created to ask that legal action be withdrawn in Archie's case. So far, more than 89,000 people have signed it.

A GoFundMe page has also been set up on the boy's behalf. So far, the account has raised 29,042 GBP (or approximately $35,479 in U.S. dollars).

Archie's mom told Christian Concern earlier this month that the judge's ruling that he's "likely" to be dead is not good enough.

"Basing this judgment on an MRI test and that he is 'likely' to be dead, is not good enough. This is believed to be the first time that someone has been declared 'likely' to be dead based on an MRI test," she explained.

"The medical expert opinion presented in Court was clear in that the whole concept of 'brain death' is now discredited, and in any event, Archie cannot be reliably diagnosed as brain-dead," Dance continued.

She reiterated that she does not believe her son has been given enough time to heal.

"I do not believe Archie has been given enough time. From the beginning, I have always thought 'why the rush?' His heart is still beating, he has gripped my hand, and as his mother, I know he is still in there," she noted.

"Until it's God's way, I won't accept he should go. I know of miracles when people have come back from being brain dead," Dance said.

Andrea Williams, chief executive of the Christian Legal Centre, said in a statement that Archie's case has raised "significant moral, legal and medical questions as to when a person is dead."

"Archie's parents believe that the time and manner of his death should be determined by God and claim a right to pray for a miracle until and unless that happens. That belief must be respected. The ideology of 'dignity in death', meaning a planned time of death as fixed and carried out by the doctors, should not be brutally imposed on families who do not believe in it," Williams said.

"We will continue to stand with the family as they appeal the ruling and continue to pray for a miracle," she concluded.

View post:
Parents of 12-Year-Old Boy Praying for a Miracle, Appealing UK Judge's Decision to Remove Life Support - CBN.com

Spinal Cord Stem Cells Comments Off on Parents of 12-Year-Old Boy Praying for a Miracle, Appealing UK Judge’s Decision to Remove Life Support – CBN.com | June 30th, 2022

The end of Roe v. Wade will not only jeopardize access to abortion in many states, it could have wide-ranging and unpredictable consequences for medical care, including fertility treatment, contraception, and cancer care.

This post-Roe world will be, in many ways, a new era for medical care in the United States, one that could transform medical services for conditions that range far beyond pregnancy, either by making them illegal or by putting their legality in question.

The consequences are unpredictable. Michelle Banker, director of reproductive rights and health litigation at the National Womens Law Center, told me in an interview before Fridays decision that the effect on other types of health care will depend upon the answers to open and untested questions in US courts. Some of it will rest on how judges will interpret new state abortion bans. States could also be emboldened by the Supreme Courts ruling to pass new legislation that restricts other medical services.

History would suggest places that outlaw abortion tend to have less access to other reproductive care as well. In Ireland, which only recently legalized abortion, there is still less access to in vitro fertilization and certain contraceptives than in the rest of Europe, even after abortion became legal. In the US, a health system that is already fractured will become even more so, limiting access to medical care particularly for marginalized patients. Whether you can get certain health care services may be predicated on where you live (or whether you can afford to travel).

The breadth of the potential health care consequences is so broad, Banker said. The first place to start is this is going to result in the death of pregnant people.

The United States has the highest maternal mortality rates among wealthy nations; Black Americans have a significantly higher mortality rate than anywhere else in the developed world. The risk of death from carrying a pregnancy to term is much higher than the risk of death from undergoing an abortion. One estimate puts the number of forced birth in the first year after Roe is overturned at 75,000; the maternal mortality rate in the US is about 1 in 10,000.

The impact the end of Roe could have on pregnancy care could reach much further. As the Atlantics Sarah Zhang wrote, pregnant women undergo genetic and other tests throughout their pregnancy, meant to assess the health of the fetus and identify any anomalies that could be fatal or life-altering. In some cases, parents who learn about these anomalies choose abortion. But that may no longer be so simple if abortion is now outlawed or severely limited. Decisions about whether to get genetic testing and when could be affected.

By the same token, most abortion bans would carve out exceptions if the health of the mother were in jeopardy. But whether a complication represents a life-threatening risk to the mothers health is in part a judgment call on the part of her doctor and the possibility of legal consequences could make the cost of mistakes much higher.

At the very least, there may well be a chilling effect due to providers and patients uncertainty as to whether treatment could expose them to civil or criminal liability, Banker said.

Fetal personhood laws that convey constitutional protections to unborn fetuses would further limit a pregnant persons choices in medical care. Several states have attempted to pass such a law, but they have thus far been held up by the courts. This new post-Roe jurisprudence could embolden those states and others to put such measures into place. Law enforcement or private citizens, depending on the state law, could bring complaints. The recently signed Texas law, for example, deputizes private citizens by creating a financial incentive for them to take civil action against people who seek or provide abortions.

Or, in a less extreme example, what happens if a pregnant person is also receiving cancer treatment or taking mental health medication that could affect the health of their fetus? If they stop receiving that medical care, their health could be in danger. But if they continue to receive it, the fetus could be affected. What are they and their doctor supposed to do?

The laws that criminalize abortion are going to impact medical decision-making, and thats terrifying, Banker said.

Supporters of abortion rights fear that, unchained by the Supreme Court, states could push deeper and deeper into the lives of pregnant women and the decisions they make about how to conduct themselves.

People have been arrested for substance use during pregnancy, based on reasoning that they are harming the growth of the pregnancy. Tennessee passed the first law permitting the prosecution of pregnant women who use drugs. That alone is objectionable to people who oppose a criminalized approach to substance use. But they also worry that such laws are just the tip of the iceberg in a post-Roe reality. Could a pregnant woman be charged with a crime if she drinks a glass of wine? Or if she goes on a hiking trip that a complainant thinks would imperil the health of her fetus?

These questions will be answered by the specifics of state laws and the discretion of prosecutors in different places. But they are questions that were unfathomable just a few months ago.

How far down this path could states go? said Elizabeth Nash, who tracks state policy at the Guttmacher Institute, in an interview before Fridays Supreme Court ruling. That might sound a bit far-fetched to people but we have seen states take drastic actions in relation for some pregnant people.

Beyond medical care during pregnancy, the end of Roe could usher in a wave of new restrictions on access to contraception and fertility treatment.

The right to contraception is currently upheld by two previous Supreme Court decisions: Griswold v. Connecticut enshrined the right for married people and Eisenstadt v. Baird did the same for unmarried people.

But the current Court is clearly not bound by those precedents if they are willing to overturn Roe v. Wade. And some prominent Republicans, such as Sen. Marsha Blackburn (R-TN), have referred to those prior court decisions as constitutionally unsound in the days since the Alito draft leaked.

That puts case law in jeopardy because it relies on this idea that rights not specifically named in the Constitution are only entitled to special protection if they are deeply rooted in the nations traditions, Banker said.

Other experts I spoke to agreed. The stage is very much set for state legislators to ban contraception if they want to, Sean Tipton, who works on policy issues at the American Society for Reproductive Medicine, told me before the Supreme Court ruled.

Would state legislators want to ban condoms or even birth control pills? Maybe not. But new laws or even state abortion bans could target other kinds of birth control.

Many of these states want to define the beginning of life as early as possible in the biological process. Oklahoma, for one, passed a law that recognized an unborn childs life as beginning at fertilization. Other states describe the moment of conception. But, as Tipton pointed out, the early stages of pregnancy are, medically speaking, a process. There is not a single moment of conception.

But if states define life in such a way, then contraceptives that could prevent a fertilized egg from becoming implanted could be under threat.

IUDs and the morning-after pill would be threatened under such a legal regime. In the vast majority of cases, IUDs work by preventing fertilization: the sperm and the egg never meet in the first place. But they also might prevent implantation under certain circumstances. There is also some controversy about whether Plan B, the morning-after pill, prevents fertilization in the first place or whether it blocks the implantation of a fertilized egg. The latter could arguably be illegal in states that recognize life at fertilization. Lawmakers in Idaho, for example, announced hearings on whether to ban emergency contraceptives and possibly IUDs before the Supreme Court had even issued its final ruling.

Then there are fertility treatments particularly in vitro fertilization that depend on fostering a larger number of eggs but typically only use a small number of them. If an embryo is conferred the same rights as a toddler, are those procedures suddenly illegal?

As Tipton put it to me, what if a doctor puts 199 embryos in a freezer for IVF treatment, and 198 of them come out of the freezer okay? Does that mean a homicide has been committed? he said.

Experts imagine other possible restrictions on procedures like IVF, particularly in states that define life as beginning at conception or fertilization. That alone could put IVF in legal jeopardy. States could also institute new restrictions on those procedures, now that the right to privacy has been redefined. Maybe the number of embryos could be limited. Maybe state legislators restrict which people are allowed to avail themselves of those services to only straight married couples, for example.

And while there is a tension between ostensibly pro-life politicians restricting access to fertility care, there is an expectation that anti-abortion advocates would be willing to let these medical services be collateral damage in order to achieve the goal of outlawing abortion.

Most right-to-life proponents are not interested in doing anything to hurt fertility patients, Tipton said. But theyre very willing to throw those patients under the bus to end abortion.

The new jurisprudence could also affect access to health care that has nothing to do with pregnancy or reproduction, experts say.

Medical care for people undergoing a gender transition would be one possible casualty. The decision in particular puts gender-affirming care in its crosshairs, Banker said.

In the opinion, Alito cited a 1974 decision, Geduldig v. Aiello, that takes what Banker calls a very narrow and cramped view of what constitutes sex discrimination. For Alitos purposes, that narrow view of sex discrimination supports the argument that banning abortion would not constitute discrimination against pregnant people on the basis of sex.

But Banker says the same logic could be applied to gender-affirming health care such as surgery or hormonal treatments. If the Supreme Courts definition of sex discrimination is now much narrower than it used to be, then opponents of those services could argue that denying a person gender-affirming medical care is not actually discriminatory.

Those arguments are easily refuted under modern precedent, Banker told me. But the drafts language and citation to Geduldig raises concerns that we may see those arguments gain more traction.

Old battles over medical research or treatment could also resurface, Tipton said. Modern science has developed treatments for spinal cord injuries, myelofibrosis, and even certain cancers by relying on stem cells. More treatments are in clinical trials right now. But their prospects could be compromised if access to those materials is limited. Some stem cells are collected from adult body tissue, but others come from embryos.

Much of this will depend on how aggressive anti-abortion advocates decide to be, and on the success of abortion rights advocates in mounting a political and legal response to a ruling overturning Roe.

But it will undoubtedly be a new era for health care in the United States, with potentially devastating consequences for patients with a wide array of medical needs.

Originally posted here:
The end of Roe v. Wade affects more than just abortion - Vox.com

Spinal Cord Stem Cells Comments Off on The end of Roe v. Wade affects more than just abortion – Vox.com | June 30th, 2022

A paper recently published in the journal Biomaterials reviewed the new advances in three-dimensional bioprinting (3DBP) for regenerative therapy in different organ systems.

Study:Advances in 3D bioprinting of tissues/organs for regenerative medicine and in-vitro models. Image Credit:luchschenF/Shutterstock.com

Organ/tissue shortage has emerged as a significant challenge in the medical field due to patient immune rejections and donor scarcity. Moreover, mimicking or predicting the human disease condition in the animal models is difficult during preclinical trials owing to the differences in the disease phenotype between animals and humans.

3DBP has gained significant attention as a highly-efficient multidisciplinary technology to fabricate 3D biological tissue with complex composition and architecture. This technology allows precise assembly and deposition of biomaterials with donor/patients cells, leading to the successful fabrication of organ/tissue-like structures, preclinical implants, and in vitro models.

In this study, researchers reviewed the 3DBP strategies currently used for regenerative therapy in eight organ systems, including urinary, respiratory, gastrointestinal, exocrine and endocrine, integumentary, skeletal, cardiovascular, and nervous systems. Researchers also focused on the application of 3DBP to fabricate in vitro models. The concept of in situ 3DBP was discussed.

In this extensively used low-cost bioprinting method, rotating screw gear or pressurized air is used without or with temperature to extrude a continuous stream of thermoplastic or semisolid material. Different materials can be printed at a high fabrication speed using this technology. However, low cell viability and the need for post-processing are the major drawbacks of extrusion bioprinting.

In this method, liquid drops are ejected on a substrate by acoustic or thermal forces. High fabrication speed, small droplet volume, and interconnected micro-porosity gradient in the fabricated 3D structures are the main advantages of this technique. However, limited printed materials and clogging are the biggest drawbacks of inkjet bioprinting.

A laser is used to induce the forward transfer of biomaterials on a solid surface in the laser-assisted bioprinting method. High cell viability and nozzle-free noncontact process are the biggest advantages of laser-assisted bioprinting, while metallic particle contamination and the time-consuming nature of the printing process are the major disadvantages.

Several studies were performed involving the development of neuronal tissues using the 3DBP method. The pressure extrusion/syringe extrusion (PE/SE) bioprinting technique was used for central nervous tissue (CNS) tissue replacement. The layered porous structure was fabricated using glial cells derived using human induced pluripotent stem cell (iPSC) and a novel bioink based on agarose, alginate, and carboxymethyl chitosan (CMC) formed synaptic networks and displayed a bicuculline-induced enhanced calcium response.

Similarly, stereolithography (SLA) was used to fabricate a 3D scaffold for CNS and the viability of the scaffold was evaluated for regenerative medicine application. Layered linear microchannels were printed using poly(ethylene glycol) diacrylate-gelatin methacrylate (PEGDA-GelMA) and rat E14 neural progenitor cells (NPCs). The 3D scaffold restored the synaptic contacts and significantly improved the functional outcomes. Cyclohexane was used to bond polystyrene fibers to matrix bundle terminals during crosslinking.

Multiphoton excited 3-dimensional printing (MPE-3DP) was employed for the regeneration of myocardial tissue. A layer-by-layer structure was fabricated using GelMA/ sodium 4-[2-(4-morpholino)benzoyl-2-dimethylamino]-butylbenzenesulfonate (MBS) and human hciPSC-derived cardiomyocytes (CMs), endothelial cells (ECs), and smooth muscle cells (SMCs). The crosslinking was performed by photoactivation. The structure promoted electromechanical coupling and improved cell proliferation, vascularity, and cardiac function.

Fused deposition modeling (FDM) and PE/SE bioprinting method were used for complex tissue and organ regeneration. A micro-fluid network heart shape structure was fabricated using polyvinyl alcohol (PVA), agarose, sodium alginate, and platelet-rich plasma and rat H9c2 cells and human umbilical vein endothelial cells (HUVECs). 2% calcium dichloride was used during the crosslinking mechanism. The fabricated structure possessed a valentine heart with hollow mechanical properties and a self-defined height.

SE printing was utilized to fabricate a capillary-like network using collagen type1/ xanthan gum and human fibroblasts and ECs for applications in blood vessels. The fabricated network possessed endothelial networks and sprouting between the fibroblast layers.

Bone, cartilage, and skeletal muscle tissue can be repaired and regenerated using the 3DBP technique. For instance, FDM printing was used to print multifunctional therapeutic scaffolds for the treatment of bone. Filopodial projections were fabricated using polylactic acid (PLA) platform loaded with hyaluronic acid (HA)/ iron oxide nanoparticles (IONS)/ minocycline and human MG-63 and human bone marrow stromal cells (hBMSCs), which improved the osteogenic stimulation of the IONS and HA.

PE/SE method was used to fabricate disks and cuboid-shaped scaffolds using - tricalcium phosphate (TCP) microgel and human fetal osteoblast (hFOB) and bone marrow-derived mesenchymal stem cell (BM-MSC) for bone repair, multicellular delivery, and disease model. The fabricated structures promoted osteogenesis.

PE/SE bioprinting was also utilized to fabricate complex porous layered cartilage-like structures using alginate/gelatin/HA, rat bone marrow mesenchymal stem cells (BMSCs), and cow cardiac progenitor cells (CPCs) for hyaline cartilage regeneration. The CPCs upregulated gene expression of proteoglycan 4 (PRG4), SRY-box transcription factor 9 (SOX9), and collagen II.

PE/SE printing was also used to fabricate multinucleated, highly-aligned myotube structures using polyurethane (PU), poly(-caprolactone) (PCL), and mouse C2C12 myoblasts and NIH/3T3 fibroblasts for in-situ expansion and differentiation of skeletal muscle tendon. The fabricated constructs demonstrated more than 80% cell viability with initial tissue differentiation and development.

SLA bioprinting technique was used to fabricate bi-layered epidermis-like structure using collagen type I, mouse NIH 3T3 fibroblast cells, and human keratinocyte cells for tissue model and engineering. The fabricated constructs effectively imitated the tissue functions.

Similarly, PE was employed to fabricate microporous structures using human amniotic mesenchymal stem cells (AFSCs) and heparin-HA-PEGDA for wound healing. The construct improved the wound closure and reepithelialization, increased extracellular matrix synthesis and vascularization, and prolonged the cell paracrine activity.

PE technique was utilized to prepare a multilayered cornea-like structure using human keratocytes and methacrylated collagen (ColMA)-alginate. The cell viability of the keratocytes decreased from 90% to 83% after printing.

PE/SE bioprinting was utilized to bioprint multilayered liver-like structures using GeIMA and human HepG2/C3A for liver tissue engineering. Similarly, hepatocytes were also bioprinted to fabricate multiple organ precursors with branching vasculature. A small intestine model with improved intestinal function and high cell proliferation was fabricated using caco-2 cell-loaded polyethylene vinyl acetate (PEVA) scaffold.

Spheroids of mesenchymal stem cells (MSCs) and chondrocytes and lung endothelial cells were utilized to fabricate scaffold-free tracheal transplant. After implantation in the rat model, the matured spheroids displayed excellent vasculogenesis, chondrogenesis, and mechanical strength. FDM technique was used to fabricate a glomerular structure for kidneys using human iPSCs and hydrogel and a hollow porous network using poly(lactic-co-glycolic acid (PLGA)/PCL/tumor-associated endothelial cells (TECs) for the urethra.

In in-situ bioprinting, the tissue is directly printed on the specific defect or wound site in the body for regenerative and reparative therapy. This method provides a well-defined structure and reduces the gap between host-implant interfaces. In-situ bioprinting is better than in vitro bioprinting techniques as the patients body, as a natural bioreactor, provides a natural microenvironment.

Several studies have evaluated this technique for tissue regeneration. For instance, PE/SE method was used for skin tissue regeneration in pigs and mice using fibrin/collagen/HA and human fibroblast cells. Skin-laden sheets of consistent composition, thickness, and width were formed upon rapid crosslinking of biomaterial. PE/SE technique was also used for neural tissue regeneration in mice using agarose/CMC/alginate and human iPSCs.

In vitro models provide significant assistance in understanding the mechanism of therapeutics and disease pathophysiology. Recently, in vitro models of human tissues and organs were engineered using 3DBP technology for safety assessment and drug testing.

In the 3DBP of organs and tissues, biomaterials play a crucial role in maintaining cellular viability, providing support, and long-term acceptance. Specifically, bioinks must possess unique properties, such as cell growth promotion and structural stability, that can be optimized for clinical use. Additionally, bioinks must be compatible with printers for high-precision rapid prototyping.

Bioinks fulfilling all of these requirements are yet to be identified. Moreover, managing the time during the bioprinting of the constructs is another major challenge, as the time required to fabricate them is often more than the survival time of cells. A bioreactor platform that supports organoid growth and provides time for tissue remodeling can be used to overcome this challenge. Ethical challenges and issues are also a hurdle since fabricating internal tissues/organs can lead to liability and biosafety concerns.

In the future, 3DBP can provide novel solutions to engineer organs/tissues and revolutionize modern healthcare and medicine if these challenges can be addressed.

More from AZoM: Building Durable and Sustainable Futures with [emailprotected]

Jain, P., Kathuria, H., Dubey, N. Advances in 3D bioprinting of tissues/organs for regenerative medicine and in-vitro models. Biomaterials 2022. https://www.sciencedirect.com/science/article/abs/pii/S0142961222002794?via%3Dihub

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Read more:
What New Advances are there in 3D Bioprinting Tissues? - AZoM

Cardiac Stem Cells Comments Off on What New Advances are there in 3D Bioprinting Tissues? – AZoM | June 30th, 2022

Global Surgical Mesh Market Is Estimated To Be Valued At US$ 1.29 Bn In 2022, And Is Forecast To Surpass US$ 2.2 Bn Valuation By The End Of 2032

Sales of surgical meshes are expected to account for more than 21 Mn units by 2032-end, owing to their increasing application in untapped markets, says a Fact.MR analyst.

Fact.MR A Market Research and Competitive Intelligence Provider: The global surgical mesh market is estimated to exceed a valuation of US$ 1.29 Bn in 2022, and expand at a significant CAGR of 5.5% by value over the assessment period (2022-2032).

The availability of surgical meshes in absorbable and non-absorbable forms has expanded their application for temporary as well as permanent reinforcement. In recent years, demand for surgical meshes has escalated in aiding breast reconstruction as they reduce the exposure risk of the implant. Increasing health literacy in North America and Europe will create ample opportunities for surgical mesh manufacturers over the coming years.

Sedentary lifestyle and increasing obesity among the population have resulted in several chronic health issues. The consequent weakening of the muscles extends space for organ prolapse and hernia. Putting these organs back in place by stitching the muscles together can result in muscle tearing and the recurrence of prolapse. However, reinforcing the weakened muscles with the help of a surgical mesh has shown to decrease recurrence and increase the longevity of the repair.

For more insights into the Market, Get A Sample of this Report!

https://www.factmr.com/connectus/sample?flag=S&rep_id=6632

Key Takeaways from Market Study

Winning Strategy

To attract new customers, market players are focusing on portfolio enhancement. Robust investments in R&D are driving product innovation for key market players. Meshes inhibiting the growth of bacterial films and preventing tissue adhesions are luring new consumers. Collaboration of manufacturers with scientific personnel and operating surgeons have enabled bespoke designing of meshes to best fit patients needs.

Manufacturers are also aiming for portfolio expansion through acquisition and partnerships. Partnering with companies that offer a well-aligned portfolio has significantly increased consumer penetration for key manufacturers. However, augmenting relations with local players and operating surgeons will be a key determinant of the products commercial success.

For Comprehensive Insights Ask An Analyst Here

https://www.factmr.com/connectus/sample?flag=AE&rep_id=6632

Scientific collaborations and robust R&D investments have also guided product innovation and became a common strategic approach adopted by leading surgical mesh manufacturing companies to upscale their market presence.

For instance:

Surgical Mesh Industry Research by Category

Surgical Mesh Market by Product Type:

Surgical Mesh Market by Nature:

Surgical Mesh Market by Surgical Access:

Surgical Mesh Market by Use Case:

Surgical Mesh Market by Raw Material:

Surgical Mesh Market by Region:

Get Customization on this Report for Specific Research Solutions

https://www.factmr.com/connectus/sample?flag=RC&rep_id=6632

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global surgical mesh market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of product type (synthetic, biosynthetic, biologic, hybrid/composite), nature of mesh (absorbable, non-absorbable, partially absorbable), surgical access (open surgery, laparoscopic surgery), use case (hernia repair, pelvic floor disorder treatment, breast reconstruction, others), and raw material (polypropylene, polyethylene terephthalate, expanded polytetrafluoroethylene, polyglycolic acid, decellularized dermis/ECM, others), across seven major regions (North America, Latin America, Europe, East Asia, South Asia & ASEAN, Oceania, MEA).

Fact. MRs Domain Knowledge in Healthcare Division

Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs

With a repertoire of over thousand reports and 1 million-plus data points, the team has analysed the healthcare domain across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services.

Check out more studies related to Healthcare Industry, conducted by Fact.MR:

Induced Pluripotent Stem Cell (iPSC) Market - Induced Pluripotent Stem Cell (iPSC) Market Analysis, By Cell Type (Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells), By Research Method (Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering), By Application (Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine) - Global Market Insights 2022 to 2026

Newborn Screening Market -Newborn Screening Market by Product (Newborn Screening Instruments, Consumables), by Test Type (Dry Blood Spot Tests, Hearing Tests, Critical Congenital Heart Disease (CCHD) Screening Tests), by Technology (Immunoassays & Enzymatic Screening Tests, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry, Others), by End User (Clinical Laboratories, Hospitals) and by Region- 2022 to 2032

Doxorubicin Market - Doxorubicin Market Analysis, By Formulation (Lyophilized Doxorubicin Powder, Doxorubicin Solution), By Cancer Type (Breast Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer, Bladder Cancer, Stomach Cancer, Leukemia), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-Commerce) - Global Market Insights 2022 to 2026

Microplate Systems Market - Microplate Systems Market By Product (Readers, Pipetting Systems & Dispensers, Washers), By End User (Biotechnology & Pharmaceuticals, Hospitals & Diagnostic Laboratories, Research Institutes, Academic Institutes) & Region - Global Market Insights 2022 to 2026

Drug Discovery Services Market - Drug Discovery Services Market Analysis by Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization and Candidate Validation), by Type (Medicinal Chemistry, Biology Services, Drug Metabolism and Pharmacokinetics) Region Forecast- 2022-2032

Lab Automation Market - Lab Automation Market by Product (Equipment, Microplate Readers, Software & Informatics, Automated ELISA Systems, Automated Nucleic Acid Purification Systems), by Application (Drug Discovery, Clinical Diagnostics, Genomics Solutions, Proteomics Solutions), & Region - Forecast to 2021-2031

Animal Model Market - Animal Model Market Analysis by Species (Rats, Mice, Guinea Pig, Rabbits, Monkeys, Dogs, Pigs, Cats, and Other Species), by Application (Basic & Applied Research and Drug Discovery/Development) and Region Forecast- 2022-2032

Blood Flow Measurement Devices Market - Blood Flow Measurement Devices Market Analysis by Product (Ultrasound - Doppler Ultrasound, Transit time Flow Meters (TTFM), Laser Doppler), Application (Non-invasive - Cardiovascular Disease, Diabetes, Dermatology, Invasive - CABG, Microvascular Surgery), by Region - Global Forecast 2022-2032

Contrast Media Injectors Market - Contrast Media Injectors Market by Product (Consumables, Injector Systems, Accessories), Application (Radiology, Interventional Radiology, Interventional Cardiology), End-User (Hospitals, Diagnostic Imaging Centers), & Regional Analysis till 2032

Preclinical Imaging Market - Preclinical Imaging Market Analysis By Product (Modality, and Reagents), and Region Forecast- 2022-2032

About Us:

Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and well be an able research partner.

Contact:

Mahendra SinghUS Sales Office:11140 Rockville PikeSuite 400Rockville, MD 20852Email: sales@factmr.comTel: +1 (628) 251-158

Read this article:
Technical Advancements & Innovative Products Likely to Expand Application of Surgical Meshes in Untapped Domains, States Fact.MR - BioSpace

Cardiac Stem Cells Comments Off on Technical Advancements & Innovative Products Likely to Expand Application of Surgical Meshes in Untapped Domains, States Fact.MR – BioSpace | June 30th, 2022

Second-line lisocabtagene maraleucel (liso-cel; Breyanzi) provides an earlier CAR T-cell treatment option that improves survival outcomes and produces a manageable safety profile in patients with relapsed/refractory large B-cell lymphoma (LBCL), including those who are older and have comorbidities, according to Nilanjan Ghosh, MD, PhD.

On June 24, 2022, the FDA approved liso-cel in the second line for patients with relapsed/refractory LBCL, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal LBCL, follicular lymphoma grade 3B, and high-grade B-cell lymphoma. This approval was supported by data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103).

Liso-cel is a fantastic option, because it has a great efficacy profile and is also a safe product amongst the available CAR T-cell products, with a relatively low incidence of cytokine release syndrome [CRS] and neurological events [NEs], the majority of which are low grade, Ghosh said.

In an interview with OncLive, Ghosh, director of the Lymphoma Program at the Levine Cancer Institute of Atrium Health, discussed the significance of the liso-cel approval in this patient population. He also highlighted how liso-cel will influence current treatment sequencing, which patients might derive the most benefit from this therapy, and the adverse effects (AEs) to be aware of and try to mitigate when prescribing liso-cel.

Ghosh: This approval is highly significant. The majority of patients with primary refractory DLBCL and early relapsed DLBCL do not derive benefit from standard-of-care [SOC] salvage chemotherapy followed by ASCT [autologous stem cell transplant], [which had been the best option until now].

The data from the TRANSFORM study showed liso-cel to be superior to high-dose salvage chemotherapy and ASCT. This approval will allow earlier access to CAR T-cell therapy for this group of patients.

Most patients with LBCL receive frontline therapy in the community setting. In addition to making our community aware of this indication, we need to educate our community about the time it takes to receive CAR T-cell therapy. The process includes many steps, such as gaining financial clearance and setting a date for T-cell collection, or leukapheresis. This date must be acceptable to both the institution [providing the treatment] and the company manufacturing the CAR T cells. [We also need to factor in] the time spent manufacturing the CAR T cells, often known as the vein-to-vein time. This entire process can take 6 weeks or more.

We often focus on just the vein-to-vein time, but there are many other steps even before leukapheresis. These patients are also refractory or have early relapsed disease that must be controlled while they are waiting to receive CAR T-cell therapy. Early referral to a CAR T-cell center is crucial to get the process going while discussing with the referring physician ways and means to control the disease in the interim. Those might include strategies like bridging therapy, which was allowed on the TRANSFORM study.

Insome patients, liso-cel may end up being a third-line therapy, despite its indication as a second-line therapy, because you may have to give another therapy to control the disease while the patients are waiting to receive CAR T cells. That discussion would best be done with the treating center and the referring physician, because some treatments can be toxic to lymphocytes, and you may want to avoid those kinds of treatments prior to collecting the lymphocytes. At the same time, we must make sure we control the disease so the patients can receive the treatment they may benefit from in the future.

Many factors must be taken into account before giving liso-cel. We look at the ECOG performance status [PS], as well as cardiac function and renal function.

Looking at comorbidities, fortunately, the TRANSCEND-PILOT-017006 trial included patients with comorbidities who were not considered good candidates for ASCT. To enroll in the study, the investigators needed to verify that the patients were not good candidates for transplant. [They also needed to meet at least 1 of the criteria], which included being over 70 years of age, having impaired renal function, having impaired cardiac function, or having a decrease in [diffusing capacity of the lungs for carbon monoxide], which is reflective of pulmonary function. The investigators also looked at hepatic function.

The outcomes of this study were good. The bottom line is that patients who are going to receive liso-cel need not only be candidates you would otherwise consider for ASCT. The eligibility for liso-cel is much broader than standard transplanteligibility in terms of age, comorbidities, and disease status. That is the most important thing. A patient who is older, has some comorbidities, and has relapsed or refractory LBCL can still benefit from liso-cel with high efficacy and low toxicity, which is what liso-cel offers in this patient population.

TRANSFORM was a randomized study of patients with DLBCL not otherwise specified, which includes de novo DLBCL and those who have transformed from indolent non-Hodgkin lymphoma; high-grade B cell lymphoma, which includes double-hit and triple-hit lymphoma; follicular lymphoma grade 3B; primary mediastinal B-cell lymphoma; and T-cell or histiocyte-rich DLBCL. Eligible patients needed to have either developed refractory disease from frontline therapy or relapsed within 12 months after frontline therapy. The frontline therapy should have included an anthracycline anda CD20 agent, which is the SOC. In addition, these patients should have been otherwise considered to be eligible for ASCT and had an ECOG PS of 0 to 1.

Eligible patients underwent leukapheresis and then were randomized to receive liso-cel or SOC, which was salvage chemotherapy followed by ASCT for those who responded to salvage chemotherapy. Importantly, this study included crossover from the SOC arm to the liso-cel arm. This was allowed for those who failed to respond to SOC by 9 weeks post-randomization, those who progressedat any time, or those who started a new antineoplastic therapy after transplant.

The primary end point was event-free survival [EFS]. Events were defined as death from any cause, progressive disease, failure to achieve complete response [CR] or partial response by 9 weeks post randomization, or the start of an antineoplastic therapy, whichever occurred first. The median EFS with liso-cel was 10.1 months compared with 2.3 months with SOC. At 12 months, the EFS rates were 44.5% with liso-cel and 23.7% with SOC. That was a significant margin of benefit.

In terms of responses, in this recent population, were most interested in CR. A total of 66% of the patients who received liso-cel achieved a CR compared with 39% of those who received SOC.

Progression-free survival [PFS] was also a secondary end point. The median PFS was 14.8 months with liso-cel and 5.7 months with SOC. Efficacy-wise, liso-cel hit all the marks. Overall survival [OS] data is maturing, so well need some longer follow-up, but we are starting to see trends in the right direction.

We have to remember that this study included crossover. Of the 91 patients in the SOC arm, 50 [crossed over to receive] CAR T-cell therapy with liso-cel. Those data will affect the OS data, but even so, were starting to see some separation of the OS curves in the TRANSFORM study.

The TRANSCEND-PILOT-017006 study is a little different because its a single-arm study. It was not intended for patients who would be otherwise considered transplant candidates. These patients did not need to relapse within 1 year [of frontline therapy], and they could have relapsed or refractory disease. A total of 25% of patients had late relapses as well, which was not the case in TRANSFORM. Otherwise, they all had 1 prior line of therapy, [like in TRANSFORM].

This is also a second-line study but in a different population of patients. This was an elderly population. Compared with the TRANSFORM study, the median age in the TRANSCEND-PILOT-017006 study was 74 years, with the oldest patient being 84 years of age. In total, 33% of patients in this study had double-hit and triple-hit disease, which I want to highlight because this is the toughest group of patients to treat. A total of 54% of the patients had primary refractory disease, [and many patients had comorbidities].

Additionally, 44% of the patients had an HCT-CI [Hematopoietic Cell Transplantation-Specific Comorbidity Index] score of 3 or more. We dont know the relevance [of this score] for CAR T-cell therapy, but outcomes are typically poor in patients who have an HCT-CI score of 3 or higher who undergoallogeneic transplant or ASCT.

[In this trial], the overall response rate was great, at 80%, with 54% achieving CR. Responses were seen in all prespecified subgroups, including patients with high-risk features, with no notable differences in efficacy or safety outcomes based on HCT-CI score. Investigators did separate out patients who had scores of less than 3 vs 3 or higher, and they didnt see any differences.

The median duration of response [DOR] was [11.2 months in patients with an HCT-CI score under 3, and not reached in patients with an HCT-CI score of 3 or higher].In patients who achieved a CR, the median DOR was 21.7 months.

The median PFS was [7.4 months in patients with an HCT-CI score under 3, and NR in patients with an HCT-CI score of 3 or higher]. The median OS was not reached.

Importantly, 32.8% of the patients were monitored as outpatients in this study, and 35% of those needed to be hospitalized for concerns of CRS and neurotoxicity after receiving liso-cel. Most of the patients who received liso-cel as outpatients did not need hospitalization within 3 days of receiving it. These results support liso-cel as a second-line treatment in patients with LBCL in whom transplant is not intended.

In general, the acute AEs that occur with any CAR T-cell therapy, but which are much lower with liso-cel, are CRS and NEs. These occur immediately post-CAR T-cell therapy, within days.

However, the incidence of CRS and NEs was low in both [TRANSFORM and TRANSCEND-PILOT-017006]. Most CRS events were grade 1 or grade 2. In total, 1 patient in each study had grade 3 CRS, and there were no instances of grade 4 CRS [in either study].

The incidence of neurotoxicity was also quite low. [A total of 4% of patients in the TRANSFORM study and 5% of patients in the TRANSCEND-PILOT-017006 study experienced] grade 3 neurotoxicity. Most of the neurotoxicity that was seen was grade 1 or grade 2. Importantly, the utilization of tocilizumab [Actemra] and steroids was also low [in both trials].

However, there are other AEs which we need to monitor. For example, by the time a patient is out of that CRS and neurotoxicity window and thinking of going back to their referring physician, they may still [be at risk for AEs such as] prolonged cytopenias, [which some patients exhibited in these trials]. In the [TRANSFORM] study, prolonged cytopenias were defined as [grade 3 cytopenias that persisted] at day 35 or beyond. [In the TRANSCEND-PILOT-017006 study, prolonged cytopenias were defined as grade 3 or higher cytopenias that persisted at day 29 or beyond.]

We should also monitor for hypogammaglobulinemia. This is important because if a patient has hypogammaglobulinemia or lymphopenia, and neutropenia, they are more prone to infection. Preventing infection, providing supportive care, and giving treatment medications [as early as possible] is important, and monitoring AEs is crucial.

The field of LBCL has exploded with new treatments over the past few years, including what we saw recently in the frontline setting. CAR T-cell therapy, in general, is a huge advancement within this field.

Having said that, its important to be aware of and monitor the AEs. A question that comes up is: How accessible are CAR T-cell therapies going to be? We need to work as a community to make them more accessible to patients, cut down the time from when we first consider CAR T-cell therapy to when we deliver it, and make that process more efficient, so more patients can benefit from it.

We also need to be aware of the many other treatments that have come out in the space, such as bispecific antibodies that are in development and antibody-drug conjugates. Over the next few years, we need to figure out how to sequence thesetherapies so that we can maximize the benefits and help our patients who still have unmet needs. We do have to recognize that even though CAR T-cell therapy has excellent outcomes, there are many patients who are still refractory to CAR T-cell therapy and relapse after CAR T-cell therapy. [We need to find] the best way to sequence the other treatments that are out there to help these patients. Thats an area of active investigation.

I hope we are in a much better place in the years to come. However, weve made huge strides in the past several years, and its been great to be a part of that research.

See original here:
Liso-cel Approval Provides Earlier, Expanded Access to CAR T-cell Therapy in Second-line LBCL - OncLive

Cardiac Stem Cells Comments Off on Liso-cel Approval Provides Earlier, Expanded Access to CAR T-cell Therapy in Second-line LBCL – OncLive | June 30th, 2022

Cells in the body have specific purposes, but stem cells are cells that do not yet have a specific role and can become almost any cell that is required.

Stem cells are undifferentiated cells that can turn into specific cells, as the body needs them.

Scientists and doctors are interested in stem cells as they help to explain how some functions of the body work, and how they sometimes go wrong.

Stem cells also show promise for treating some diseases that currently have no cure.

Stem cells originate from two main sources: adult body tissues and embryos. Scientists are also working on ways to develop stem cells from other cells, using genetic reprogramming techniques.

A persons body contains stem cells throughout their life. The body can use these stem cells whenever it needs them.

Also called tissue-specific or somatic stem cells, adult stem cells exist throughout the body from the time an embryo develops.

The cells are in a non-specific state, but they are more specialized than embryonic stem cells. They remain in this state until the body needs them for a specific purpose, say, as skin or muscle cells.

Day-to-day living means the body is constantly renewing its tissues. In some parts of the body, such as the gut and bone marrow, stem cells regularly divide to produce new body tissues for maintenance and repair.

Stem cells are present inside different types of tissue. Scientists have found stem cells in tissues, including:

However, stem cells can be difficult to find. They can stay non-dividing and non-specific for years until the body summons them to repair or grow new tissue.

Adult stem cells can divide or self-renew indefinitely. This means they can generate various cell types from the originating organ or even regenerate the original organ, entirely.

This division and regeneration are how a skin wound heals, or how an organ such as the liver, for example, can repair itself after damage.

In the past, scientists believed adult stem cells could only differentiate based on their tissue of origin. However, some evidence now suggests that they can differentiate to become other cell types, as well.

From the very earliest stage of pregnancy, after the sperm fertilizes the egg, an embryo forms.

Around 35 days after a sperm fertilizes an egg, the embryo takes the form of a blastocyst or ball of cells.

The blastocyst contains stem cells and will later implant in the womb. Embryonic stem cells come from a blastocyst that is 45 days old.

When scientists take stem cells from embryos, these are usually extra embryos that result from in vitro fertilization (IVF).

In IVF clinics, the doctors fertilize several eggs in a test tube, to ensure that at least one survives. They will then implant a limited number of eggs to start a pregnancy.

When a sperm fertilizes an egg, these cells combine to form a single cell called a zygote.

This single-celled zygote then starts to divide, forming 2, 4, 8, 16 cells, and so on. Now it is an embryo.

Soon, and before the embryo implants in the uterus, this mass of around 150200 cells is the blastocyst. The blastocyst consists of two parts:

The inner cell mass is where embryonic stem cells are found. Scientists call these totipotent cells. The term totipotent refer to the fact that they have total potential to develop into any cell in the body.

With the right stimulation, the cells can become blood cells, skin cells, and all the other cell types that a body needs.

In early pregnancy, the blastocyst stage continues for about 5 days before the embryo implants in the uterus, or womb. At this stage, stem cells begin to differentiate.

Embryonic stem cells can differentiate into more cell types than adult stem cells.

MSCs come from the connective tissue or stroma that surrounds the bodys organs and other tissues.

Scientists have used MSCs to create new body tissues, such as bone, cartilage, and fat cells. They may one day play a role in solving a wide range of health problems.

Scientists create these in a lab, using skin cells and other tissue-specific cells. These cells behave in a similar way to embryonic stem cells, so they could be useful for developing a range of therapies.

However, more research and development is necessary.

To grow stem cells, scientists first extract samples from adult tissue or an embryo. They then place these cells in a controlled culture where they will divide and reproduce but not specialize further.

Stem cells that are dividing and reproducing in a controlled culture are called a stem-cell line.

Researchers manage and share stem-cell lines for different purposes. They can stimulate the stem cells to specialize in a particular way. This process is known as directed differentiation.

Until now, it has been easier to grow large numbers of embryonic stem cells than adult stem cells. However, scientists are making progress with both cell types.

Researchers categorize stem cells, according to their potential to differentiate into other types of cells.

Embryonic stem cells are the most potent, as their job is to become every type of cell in the body.

The full classification includes:

Totipotent: These stem cells can differentiate into all possible cell types. The first few cells that appear as the zygote starts to divide are totipotent.

Pluripotent: These cells can turn into almost any cell. Cells from the early embryo are pluripotent.

Multipotent: These cells can differentiate into a closely related family of cells. Adult hematopoietic stem cells, for example, can become red and white blood cells or platelets.

Oligopotent: These can differentiate into a few different cell types. Adult lymphoid or myeloid stem cells can do this.

Unipotent: These can only produce cells of one kind, which is their own type. However, they are still stem cells because they can renew themselves. Examples include adult muscle stem cells.

Embryonic stem cells are considered pluripotent instead of totipotent because they cannot become part of the extra-embryonic membranes or the placenta.

Stem cells themselves do not serve any single purpose but are important for several reasons.

First, with the right stimulation, many stem cells can take on the role of any type of cell, and they can regenerate damaged tissue, under the right conditions.

This potential could save lives or repair wounds and tissue damage in people after an illness or injury. Scientists see many possible uses for stem cells.

Tissue regeneration is probably the most important use of stem cells.

Until now, a person who needed a new kidney, for example, had to wait for a donor and then undergo a transplant.

There is a shortage of donor organs but, by instructing stem cells to differentiate in a certain way, scientists could use them to grow a specific tissue type or organ.

As an example, doctors have already used stem cells from just beneath the skins surface to make new skin tissue. They can then repair a severe burn or another injury by grafting this tissue onto the damaged skin, and new skin will grow back.

In 2013, a team of researchers from Massachusetts General Hospital reported in PNAS Early Edition that they had created blood vessels in laboratory mice, using human stem cells.

Within 2 weeks of implanting the stem cells, networks of blood-perfused vessels had formed. The quality of these new blood vessels was as good as the nearby natural ones.

The authors hoped that this type of technique could eventually help to treat people with cardiovascular and vascular diseases.

Doctors may one day be able to use replacement cells and tissues to treat brain diseases, such as Parkinsons and Alzheimers.

In Parkinsons, for example, damage to brain cells leads to uncontrolled muscle movements. Scientists could use stem cells to replenish the damaged brain tissue. This could bring back the specialized brain cells that stop the uncontrolled muscle movements.

Researchers have already tried differentiating embryonic stem cells into these types of cells, so treatments are promising.

Scientists hope one day to be able to develop healthy heart cells in a laboratory that they can transplant into people with heart disease.

These new cells could repair heart damage by repopulating the heart with healthy tissue.

Similarly, people with type I diabetes could receive pancreatic cells to replace the insulin-producing cells that their own immune systems have lost or destroyed.

The only current therapy is a pancreatic transplant, and very few pancreases are available for transplant.

Doctors now routinely use adult hematopoietic stem cells to treat diseases, such as leukemia, sickle cell anemia, and other immunodeficiency problems.

Hematopoietic stem cells occur in blood and bone marrow and can produce all blood cell types, including red blood cells that carry oxygen and white blood cells that fight disease.

People can donate stem cells to help a loved one, or possibly for their own use in the future.

Donations can come from the following sources:

Bone marrow: These cells are taken under a general anesthetic, usually from the hip or pelvic bone. Technicians then isolate the stem cells from the bone marrow for storage or donation.

Peripheral stem cells: A person receives several injections that cause their bone marrow to release stem cells into the blood. Next, blood is removed from the body, a machine separates out the stem cells, and doctors return the blood to the body.

Umbilical cord blood: Stem cells can be harvested from the umbilical cord after delivery, with no harm to the baby. Some people donate the cord blood, and others store it.

This harvesting of stem cells can be expensive, but the advantages for future needs include:

Stem cells are useful not only as potential therapies but also for research purposes.

For example, scientists have found that switching a particular gene on or off can cause it to differentiate. Knowing this is helping them to investigate which genes and mutations cause which effects.

Armed with this knowledge, they may be able to discover what causes a wide range of illnesses and conditions, some of which do not yet have a cure.

Abnormal cell division and differentiation are responsible for conditions that include cancer and congenital disabilities that stem from birth. Knowing what causes the cells to divide in the wrong way could lead to a cure.

Stem cells can also help in the development of new drugs. Instead of testing drugs on human volunteers, scientists can assess how a drug affects normal, healthy tissue by testing it on tissue grown from stem cells.

Watch the video to find out more about stem cells.

There has been some controversy about stem cell research. This mainly relates to work on embryonic stem cells.

The argument against using embryonic stem cells is that it destroys a human blastocyst, and the fertilized egg cannot develop into a person.

Nowadays, researchers are looking for ways to create or use stem cells that do not involve embryos.

Stem cell research often involves inserting human cells into animals, such as mice or rats. Some people argue that this could create an organism that is part human.

In some countries, it is illegal to produce embryonic stem cell lines. In the United States, scientists can create or work with embryonic stem cell lines, but it is illegal to use federal funds to research stem cell lines that were created after August 2001.

Some people are already offering stem-cells therapies for a range of purposes, such as anti-aging treatments.

However, most of these uses do not have approval from the U.S. Food and Drug Administration (FDA). Some of them may be illegal, and some can be dangerous.

Anyone who is considering stem-cell treatment should check with the provider or with the FDA that the product has approval, and that it was made in a way that meets with FDA standards for safety and effectiveness.

More here:
Stem cells: Sources, types, and uses - Medical News Today

Skin Stem Cells Comments Off on Stem cells: Sources, types, and uses – Medical News Today | June 30th, 2022

Alopecia is an autoimmune disorder where immune cells attack and destroy hair follicles, causing hair loss. Uncovering a molecular target of a common treatment for alopecia in a new study, scientists at the Salk Institute claim regulatory T cells (Tregs) and glucocorticoids do not just suppress the immune system, they also make hair grow.

Originally discovered as a specialized subset of T lymphocytes that suppress excessive immune response and maintain balance in immune functions, recent studies have shown Tregs also play a role in tissue repair and regeneration.

First author of the study, Zhi Liu PhD, a research associate at Salk Institute said, We were fascinated by Tregs non-traditional function in tissue repair and the way they communicate with tissue stem cells to facilitate tissue regeneration.

Balance in tissue niches depends on communications between stem cells and supporting cells. That Tregs communicate with stem cells and play a critical role in balancing self-renewal and differentiation in stem cell niches has been reported in earlier studies. Yet, how Tregs sense signals in tissue microenvironments and communicate with stem cells has been unclear until now.

Liu said, Our study identified the glucocorticoid hormone as the upstream signal that alerts Tregs, and the growth factor TGF-beta3 as the downstream signal that promotes stem cell activation and hair regeneration. These signals could be potentially conserved in other tissue injury and repair processes.

The study, led by Ye Zheng, PhD, an associate professor at Salk Institute for Biological Studies in La Jolla, California, was published on June 23, 2022, in an article in the journal Nature Immunology titled Glucocorticoid signaling and regulatory T cells cooperate to maintain the hair-follicle stem-cell niche. The findings explain how Tregs interact with stem cells in the skin using the steroid hormone glucocorticoid as a messenger to generate new hair follicles and promote hair growth. This regenerative role of Treg cells is independent of its immunosuppressive functions.

Zhengs team was initially interested in uncovering the role of Tregs and glucocorticoids in autoimmune dysfunctions such as multiple sclerosis, Crohns disease, and asthma. However, they detected no functional significance of glucocorticoids or Tregs in these diseases. They then focused on the skin because here Tregs express high levels of glucocorticoid receptors.

The researchers shaved hair off the back of adult mice that lacked the gene encoding the glucocorticoid receptor in their Tregs or had a normal set of genes. After two weeks, the normal mice grew back their hair, but the mice without glucocorticoid receptors barely could, said Liu. It was very striking, and it showed us the right direction for moving forward.

The findings indicated a glucocorticoid-mediated communication between Tregs and stem cells in hair follicles that need to be activated for hair regeneration. Moreover, the authors showed lack of the glucocorticoid receptor in Tregs blocked hair regeneration without affecting immune balance.

After hair loss, skin cells stained blue, from a normal mouse can activate hair follicle stem cells, stained red [left], whereas skin cells in mice without glucocorticoid receptors in their regulatory T cells cannot activate hair follicle stem cells [right] (Salk Institute).The authors found glucocorticoids instruct Tregs to activate hair follicle stem cells (HFSCs), which leads to hair growth. This crosstalk between the T cells and the stem cells depends on a mechanism whereby glucocorticoid receptors cooperate with a regulatory protein in Tregs called Foxp3, to induce a growth factor called transforming growth factor beta3 (TGF-beta3), which then activates the signaling molecules Smad2/3 in HFSCs to stimulate stem cell proliferation and differentiation into new hair follicles, promoting hair growth. The authors uncovered Tregs dont usually produce TGF-beta3, as they do in the skin. Databases analysis revealed this phenomenon occurs in injured muscle and heart tissue, similar to how hair removal simulated a skin tissue injury in this study.

In acute cases of alopecia, immune cells attack the skin tissue, causing hair loss. The usual remedy is to use glucocorticoids to inhibit the immune reaction in the skin, so they dont keep attacking the hair follicles, said Zheng. Applying glucocorticoids has the double benefit of triggering the regulatory T cells in the skin to produce TGF-beta3, stimulating the activation of the hair follicle stem cells.

In future studies, Zheng and his team would like to explore whether compromised glucocorticoid signaling in Tregs of the skin can cause alopecia. Zheng said, It will be interesting to see if skin Treg cells can be targeted for the treatment of alopecia patients.

Beyond the regeneration of hair follicles, Zheng would like to build upon studies that have shown Tregs help repair and regenerate multiple tissue types. They will study other injury models and isolate Tregs from injured tissues to monitor increased levels of TGF-beta3 and other growth factors.Wed like to explore whether glucocorticoids function as a universal signal to trigger Tregs non-traditional function to promote tissue regeneration.

More:
Hair Regeneration Requires Regulatory T Cells Signal Skin Stem Cells - Genetic Engineering & Biotechnology News

Skin Stem Cells Comments Off on Hair Regeneration Requires Regulatory T Cells Signal Skin Stem Cells – Genetic Engineering & Biotechnology News | June 30th, 2022

Hematopoietic Stem Cells: In living organisms, a specialized system that consist of blood and its progenitors are referred to as the hematopoietic system.

In particular, this system is made up of cells with specialized functions such as the red blood cells (for carrying oxygen to tissues), white blood cells (for immune defense against pathogens, and foreign agents), platelets (for blood clotting), macrophages and lymphocytes (also for immune defense).

However, many of the said blood cells are temporary and need to be replaced with new ones continuously. But fret not because a single cell can solve the problem!

Every day, almost billions of new blood cells are synthesized within the body with each coming from a specific progenitor cell called the hematopoietic stem cell.

How to pronounce Hematopoietic Stem Cells?

What is Hematopoiesis?

The formation of all kinds of blood cells including creation, development, and differentiation of blood cells is commonly known as Hematopoiesis or Haemopoiesis.

All types of blood cells are generated from primitive cells (stem cells) that are pluripotent (they have the potential to develop into all types of blood cells).

Also referred to as hemocytoblasts, hematopoietic cells are the stem cells that give rise to blood cells in hematopoiesis.

Where Does Hematopoiesis Occur?

In a healthy adult, hematopoiesis occurs in the bone marrow and lymphatic tissues, where 1000+ new blood cells (all types) are generated from the hematopoietic stem cells to main the steady-state levels.

Where Are Hematopoietic Stem Cells Found?

They can also be found in the umbilical cord and in the blood from the placenta.

Who Discovered Hematopoietic Stem Cells?

It was long believed that the majority of hematopoiesis occurs during ontogeny (origination and development of organism) and that the mammalian hematopoietic system originated from the yolk sac per se.

Functions of Hematopoietic Cells

As alluded to earlier, blood cells and blood cell components are formed in a process called hematopoiesis.

Coming from the Greek words hemato and poiesis which mean blood and to make respectively, hematopoiesis occurs in the bone marrow and is responsible not only for the synthesis but also the multiplication, and differentiation of blood cells.

Shown below is a diagrammatic illustration of the different blood cell types that hematopoietic cells can give rise to:

Clinical uses of Hematopoietic Stem Cells

The mammalian blood system showcases the equilibrium between the functions of hematopoietic stem cells. Intensive studies have already shown the structures and molecules that control these stem cells, but the exact picture of the underlying molecular mechanisms is still unclear.

Above everything else, it is important to note that such issues are not just of academic interest but can also be relevant in devising future novel methods of diagnosing and treating various diseases associated with cells.

Key References

Read the rest here:
Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions

Skin Stem Cells Comments Off on Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions | June 30th, 2022

Research into the retina and optic nerve using stem-cell models has unveiled specific genetic markers of glaucomathe worlds leading cause of permanent blindness possibly opening up new treatments for the condition.

Glaucoma is a blanket term describing a group of eye conditions that do damage to the retinal ganglion cellsneurons near the inner eye that make up the optic nerve. The optic nerve is the part of the eye that receives light and transmits it to the brain; thus, the damage that glaucoma does leads to permanent blindness. Thecondition is predicted to affect around 80 million people by 2040, yet treatments are extremely limited.

This study linked 97 genetic clusters to the damage done by the most common form of glaucoma, primary open-angle glaucoma or POAG, revealing important genetic components that control the way the condition attacks. POAG is a genetically complicated condition that is likely hereditary and, at the moment, cannot be stopped or reversed. The only treatment of POAG available involves releasing pressure on the eye, and this will only slow down the condition.

The research project was led jointly by the Garvan Institute of Medical Research, the University of Melbourne, and the Centre for Eye Research Glaucoma.

We saw how the genetic causes of glaucoma act in single cells, and how they vary in different people, said joint lead author of the study and Melbourne University academic, Prof. Joseph Powell, in a Garvan Institutemedia release.

Current treatments can only slow the loss of vision, but this understanding is the first step towards drugs that target individual cell types, Powell said.

The research behind the discoverywas published in the journalCell Genomicsand wasthe result of a lengthy collaboration between Australian medical research centres involving the investigation of complicated diseases and their underlying genetic causes, using stem-cell modelling; which the researchers said demonstrated the success of this study and the power of this approach.

Previously, glaucoma research was limited because samples of the optic nerve could not be obtained from participants in a non-invasive fashion. However, stem-cell modelling addressed this issue as it allowed researchers to develop optic nerve samples from skin, a much easier part of the body to extract.

The team administered skin biopsies on183 participants, 91 of whom had advanced primary open-angle glaucoma, to gather skin cells that they could reprogram to revert into stem cells and then guide into becoming retinal cells. Of the 183 samples collected, 110 samples, 54 from participants with POAG, were successfully converted from skin cells into retinal, and over 200,000 of these converted cells were sequenced to generate molecular signatures.

The researchers of this study employedsingle-cell RNA genetic sequencing in order to study individual cells. This form of sequencing creates an incredibly detailed genetic map, which looks for genetic variations that affect the expressionthe process of turning instructions from DNA into functional products like proteins of one or more genes. Through identifying these key genes, further deductions on the influence that genetic variations have on glaucoma can be made.

The signatures of those with and without glaucoma were compared to establish key genetic components that control the way that glaucoma attacks the retina.

The researchers first identified, using the signatures of both those with and without glaucoma,312 genetic variants associated with the ganglion cells that eventually degenerate in a person living with POAG. Further analysis of the genes associated with POAG linked the 97 clusters mentioned above to the damage done by glaucoma.

Another joint-lead author of the paper and Melbourne University professor, Alice Pebay, said that by studying glaucoma in retinal cells, a context-specific profile of the disease was created.

We wanted to see how glaucoma acts in retinal cells specificallyrather than in a blood sample, for instanceso we can identify the key genetic mechanisms to target, Pebay said.

Equally, we need to know which genetic variations are healthy and normal, so we can exclude them from a treatment.

To improve the understanding of complex conditions such as glaucoma, researchers noted it was important to establish a profile of the disease which promotesthe understanding of causes, risks and fundamental mechanisms of diseases. Furthermore, genetic investigations are critical to drug development and pre-clinical trials because they assist in constructing complete human models of diseases.

University of Tasmania professor and a third joint-lead author of the paper,Alex Hewitt said that the findings of this study set up future research into novel glaucoma treatments.

Not only can scientists develop more tailored drugs, but we could potentially use the stem-cell models to test hundreds of drugs in pre-clinical assays, said Hewitt.

This method could also be used to assess drug efficacy in a personalised manner to assess whether a glaucoma treatment would be effective for a specific patient.

Go here to read the rest:
Secrets of Permanent Blindness Revealed by Stem-cell Research - The Epoch Times

Skin Stem Cells Comments Off on Secrets of Permanent Blindness Revealed by Stem-cell Research – The Epoch Times | June 30th, 2022

This is the season to soak up the warm, wonderful sun and show off our glowing skin in shorts, tanks and bathing suits.

But this time of year can be most treacherous for skin we can get blasted by everything from poison ivy and mosquitoes to sunburns if were not careful. And even just a little bit of extra sun means we should be doubling down on our hydration and moisturizing, and pulling out the big-gun products to help keep our skin safe.

One of my new favorite products is Lancme Rnergie H.C.F. Triple Serum ($135 on Lancome-usa.com) Its a triple-dose serum that targets volume loss, wrinkles and dark spots, and helps prevent damage with hyaluronic acid, vitamin C+, niacinamide and ferulic acid. That means its a gel, a cream and an emulsion a combo that results in both hydration and moisturizing (the first adds water; the second softens dry skin, so theyre not the same things, and we do indeed need both).

And if the aforementioned glowing is on your summer skin to-do list, then reach for Pat McGrath Labs Divine Skin: Rose 001 The Essence ($86 on Patmcgrath.com). It boosts moisture big-time, illuminates, softens and smooths with natural floral ingredients. Apply it to your face in between cleansing and moisturizing every morning to nourish and replenish the skin barrier, There are zero silicone, parabens, sulfates, gluten, mineral oil and phthalates.

Onto sunscreens. For starters, make SPF a year-round thing, if you havent already. Its your safeguard against hyperpigmentation, inflammation, fine lines and, yes, skin cancer. Use it on your face all year, and then on your body too, especially this time of year. Get one with broad-spectrum coverage (to shield you from both UVB rays that cause burning and UVA rays that cause lasting damage) and with an SPF of 30 or higher. And choose one that smells good, if you have the option. On that front, Chanels UV Essentiel ($55 on chanel.com) is as light in texture as it is in its fragrance a delicate floral that smells fresh as can be.

For anyone with acne-prone skin, non-oily formulas are imperative. Look for liquid sunscreens instead of thick creams that clog pores. A great choice is TIZO 2 Non-Tinted Facial Mineral Sunscreen SPF 40 ($43 on amazon.com).

And if youre in the opposite situation and concerned about dry skin instead go in big for moisturizing and hydration, with EleVen by Venus Williams: Natural Unrivaled Sun Serum ($50 on elevenbyvenuswilliams.com). Its a lightweight mineral protection, SPF 35 and is safe for reefs (so wear it on any beach you like before swimming), cruelty-free, and vegan. It also blends in incredibly well, has a velvety finish, and contains prickly pear extract, to hydrate and soothe inflamed skin in case youve gotten a sunburn.

For sunburns, an RX treatment may be in order. At my day spa, GSpa at Foxwoods, we offer a Soothing Facial ($175 for 50 minutes at foxwoods.com) that uses antioxidants, peptides and botanical stem cells. Each of those ingredients protects the skin from free radical damage and restores hydration soothing and refreshing dry and sensitive skin.

See the original post here:
Youve got skin in the game protect it from summer sun damage - Boston Herald

Skin Stem Cells Comments Off on Youve got skin in the game protect it from summer sun damage – Boston Herald | June 30th, 2022

Express News Service

BENGALURU: Vitiligo, a skin de-pigmentation disorder which affects 0.1 to 8% of population, is a cause of worry especially for women as it mainly affects face, neck and hands. It relapses in 40% of patients, within a year after stopping treatment. But Mesenchymal stem cell-based therapy can be a hope, experts say.

On World Vitiligo Day on Saturday, dermatologist, Aster R V Hospital, Dr Sunil Prabhu said the disorder is affecting at least 2.16% of children/adolescents. Vitiligo is a long-term condition, where pale white patches develop on the skin due to lack of melanin pigment. According to Dr Praveen Bharadwaj, dermatology consultant, Manipal Hospital, Whitefield, vitiligo is a condition in which the patients immune system weakens which affects the normal functioning of melanin producing cells.

Dr Bharadwaj explained, Mesenchymal stem cells, which are multi-potent adult stem cells, are found in bone marrow, fat tissues, umbilical cord and human foreskin. They are promising agents for therapy for the re-pigmentation of skin in vitiligo. This therapy reduces the main trigger of vitiligo that is immune-mediated melanocyte degeneration (stopping the immune destruction of melanocytes which produces melanin), promotes melanocytes and prevents relapse of the condition, he said.

Read the original post:
Experts offer hope to vitiligo patients - The New Indian Express

Skin Stem Cells Comments Off on Experts offer hope to vitiligo patients – The New Indian Express | June 30th, 2022

Collagenits the fountain-of-youth protein that makes skin smooth and plump by stimulating tissue growth. But as the body ages and slows down its own collagen production, many turn to supplements for a fix. The downside? Theyre usually made using animal bones, skin, and cartilage. Gross. Thankfully, vegan alternatives that boost our bodys natural collagen production or actually replicate the amino acids in animal-derived collagen are totally in fashion.

Collagen is a protein the body makes naturally that can be found in hair, skin, nails, and bones. The protein is vital for keeping bones strong and skin looking wrinkle-free, and as you age, your body naturally slows down the production of collagen. The much-buzzed-about beauty trend usually refers to the intake of animal-sourced collagen that typically comes animal bones, skin, and cartilage.

There are many ways to boost your bodys collagen by eating foods high in vitamin C, zinc, and copper. These nutrients can be found in foods such as beans, oranges, broccoli, and tomatoes. As demand for plant-based collagen grows, brands are stepping up to create completely vegan collagen using genetically modified yeast and bacteria. Other innovative brands like Geltor are also utilizing high-tech methods to create vegan collagen that will be more widely available in the future. Geltors Type 21 collagen begins with a set of microbes that naturally produce proteins, which are programmed to make collagen without sourcing it cruelly from animals. Its first protein product, Collume, launched in 2018 for use in skincare formulations.

In the meantime, weve rounded up six products thatll give you the best beauty bang for your buck.

Andalou Naturals

Using a first-of-its-kind, bio-designed vegan collagen from tech company Geltor, this nourishing eye cream boasts unparalleled improvement in skin moisture. Apply day and night to let the collagen, hyaluronic acid, and fruit stem cells work their magic to revitalize tired under-eyes.Learn more here

Pacifica Beauty

A mascara that keeps lashes looking thicker and healthier after taking it off may seem too good to be true, but not when vegan beauty brand Pacifica is on the case. Formulated with vegan collagen and plant-based fibers, this glossy, black formula is a must-have for your beauty bag.Learn more here

Moon Juice

For those looking to preserve their natural collagen, why not drink it with your morning cup o joe? With this three-ingredient coffee creamer, supple skin and minimized fine lines are just a sip away thanks to a powerful combination of rice bran, silver ear mushroom, and salt of hyaluronic acid.Learn more here

Follain

A concentrated blend of niacinamide, bakuchiol (a plant-derived retinol alternative), and a peptide complex work together to bring out smoother, firmer skin and tackle signs of aging in this velvety-soft serum. Layer under moisturizer every morning and night to reap the benefits.Learn more here

Carrot & Stick

With a powerful formulation of plant proteins, vitamins, amino-collagen, and alpine rose stem cell extract, this lightweight antioxidant moisturizer nourishes skin to help smooth lines and wrinkles without any unwanted sulfates, parabens, or phthalates.Learn more here

Sourse

Chocolate and beautycould there be a better combo? An infusion of skin-boosting collagen powder and detoxifying spirulina in this low-sugar, functional dark chocolate means were just two heavenly bites away from improved skin texture and elasticity.Learn more here

For more on vegan beauty, read:The VegNews Vegan Beauty AwardsThe 8 Best Vegan Hydrating Skincare ProductsThe 10 Colorful, Vegan Makeup Products for Summer

Aruka Sanchir(@ruukes) is the Beauty & Style Editor at VegNews who is always looking for exciting new vegan products to test out.

JUST LAUNCHED! Get our 10 Easy Vegan Summer Meals recipe book as a FREE instant download.

Get the Guide

JUST LAUNCHED! Get our 10 Easy Vegan Summer Meals recipe book as a FREE instant download.

Get the Guide

Read the rest here:
What Is Vegan Collagen? And the 6 Best Products to Try - VegNews

Skin Stem Cells Comments Off on What Is Vegan Collagen? And the 6 Best Products to Try – VegNews | June 30th, 2022

The biotechs all new neurorestorative approach aims to rebuild and replace lost brain cells in Alzheimers that underlies clinical symptoms.

On the back of the trial, the company plans to launch a world-first human trial in 2024.

The veterinary trial, led by Skin2Neuron and published this month in Stem Cell Research and Therapy, reversed the dementia-like syndrome that strikes down many older pet dogs with Alzheimers.

Dementia was reversed in more than half of the canine patients, with a clinically meaningful improvement in 80%. Typically, improvement lasted around two years.

Skin2Neuron champions its new approach as a ray of hope for Alzheimers disease: championing a completely different approach to the amyloid hypothesis of Alzheimers disease.

Our target is the ultimate cause of dementia: lost neurons and synapses. We do this by microinjecting a patients own HFN cells directly into the hippocampus, the brains memory center and first area to be devastated by Alzheimers, explains the company.

While its lead therapeutic target is Alzheimers, it says its technology also has potential to treat neurodegenerative conditions such as Parkinsons disease, Amyotrophic Lateral Sclerosis and more.

A dogs thinking neocortex and hippocampus is similar to the human brain, says the company. Meanwhile, older dogs often develop a dementia syndrome similar to human dementia: becoming forgetful, irritable, lost, wandering around aimlessly, failing to recognize owners and experiencing disrupted sleep.

"Because of deep parallels between the canine brain and human brain, and canine Alzheimer's and human Alzheimer's, I started this trial 10 years ago with the assumption that if it's going to work in humans, then it needs to work in dogs first. And the results exceeded my wildest expectations, said co-founder Professor Michael Valenzuela.

"The hippocampus, the memory center of the brain, was packed with baby neurons and new synapses, precisely where we delivered the cells. Compared to untreated dogs, it was like night and day".

Microscopic analysis confirmed the dogs had classic Alzheimer pathology: meaning the cell therapy worked in the setting of natural disease, a first of its kind, according to the company.

"Given our doggie patients also had many of the same health issues that older people face, it gives me even greater confidence," said Valenzuela.

Study:Valenzuela, M., Duncan, T., Abey, A.et al.Autologous skin-derived neural precursor cell therapy reverses canine Alzheimer dementia-like syndrome in a proof of concept veterinary trial.Stem Cell Res Ther13,261 (2022). https://doi.org/10.1186/s13287-022-02933-w

Visit link:
'A new Alzheimer's treatment is on the horizon': Cell therapy reverses dementia-like syndrome in dogs - BioPharma-Reporter.com

Skin Stem Cells Comments Off on ‘A new Alzheimer’s treatment is on the horizon’: Cell therapy reverses dementia-like syndrome in dogs – BioPharma-Reporter.com | June 30th, 2022

Acute chest syndrome (ACS) is a potential complication of sickle cell disease (SCD). It involves the sudden onset of respiratory symptoms, which may lead to lung injury.

SCD is an inherited disorder that affects red blood cells. In people with SCD, red blood cells are crescent- or sickle-shaped instead of disc-shaped. This impairs their ability to carry oxygen and causes them to stick together.

A person with SCD may develop ACS if sickle cells stick together to form a blood clot in the small blood vessels within the lungs. Other possible causes include viral and bacterial lung infections and postsurgical complications.

The article below takes an in-depth look at ACS, including its causes, treatment, and prevention.

ACS is a serious and potentially life threatening condition involving sudden, severe respiratory symptoms and reduced blood oxygen levels. The condition is a potential complication of SCD.

According to the Centers for Disease Control and Prevention (CDC), the most common symptoms of ACS include:

Red blood cells contain a protein called hemoglobin, which binds to oxygen. Healthy red blood cells are disc-shaped, allowing them to move freely through blood vessels to deliver oxygen to the bodys tissues and organs.

In those with SCD, the hemoglobin inside red blood cells is abnormal and causes the cells to take on a characteristic sickle shape. These cells do not move through the blood vessels in the typical way and have a tendency to clump together.

A person with SCD may develop ACS as a result of sickle cells blocking a pulmonary blood vessel within the lungs. The Sickle Cell Disease Association of America notes that oxygen deprivation within the lungs can result in permanent lung damage. In some cases, ACS is life threatening.

Various factors can cause or contribute to ACS in SCD. Examples include:

In children, doctors are able to identify the cause of ACS in about 40% of cases. In the other cases, the triggering event is unclear.

According to the National Heart, Lung, and Blood Institute, more than 100,000 people in the United States have SCD. There are several types of SCD, each of which involves different gene mutations. According to a 2022 literature review, people with certain genotypes hemoglobin SS (Hb SS) and Hb S-beta0-thalassemia have an increased risk of developing ACS.

Some additional factors that may increase a persons risk of developing ACS include:

A diagnosis of ACS relies on both clinical symptoms and imaging tests.

Clinical symptoms that may indicate a diagnosis of ACS include:

Doctors may perform several tests to help rule out other illnesses and confirm a diagnosis of ACS. Examples include:

Without treatment, ACS may progress rapidly. Early treatment reduces the risk of complications and death.

Most people with ACS require hospitalization for careful respiratory monitoring and treatment. According to a 2017 review, treatment may include the following:

An individual cannot eliminate all risk factors for ACS. For example, people with certain genotypes of SCD have an increased risk of developing ACS. This is a nonpreventable risk factor.

However, people can take steps to reduce their risk of developing ACS. These include:

A 2017 study notes that almost half of all ACS cases develop during hospitalization. In this study, the frequency of an ACS diagnosis decreased from 22% to 12% after implementing a protocol for using incentive spirometry during hospital stays.

Among people with SCD, ACS is the second most common cause of hospitalization and one of the most common causes of death. The condition has a mortality rate of 4.3% in adults and 1.1% in children.

The outlook for people with ACS varies according to the nature and extent of any complications. Possible complications include:

The condition can also be fatal.

According to the British Society for Haematology (BSH), a person who develops ACS will require follow-up treatment, which may include blood transfusions or the chemotherapy agent hydroxycarbamide, which is also known as hydroxyurea.

Acute chest syndrome is a complication of sickle cell disease. People with ACS develop sudden respiratory symptoms, including chest pain and breathing difficulties, along with coughing, wheezing, or rales.

A person with SCD may develop ACS as a result of sickle cells sticking together and forming a blood clot within a pulmonary blood vessel. The condition can also occur due to a viral or bacterial infection, asthma, or complications following surgery.

ACS is a severe and potentially life threatening condition. However, people who receive prompt treatment tend to have a much more favorable outlook. As such, it is important that people with SCD familiarize themselves with the symptoms of ACS so that they can recognize and act on the warning signs, should they occur.

Here is the original post:
Acute chest syndrome and sickle cell disease: What is the link? - Medical News Today

Skin Stem Cells Comments Off on Acute chest syndrome and sickle cell disease: What is the link? – Medical News Today | June 30th, 2022

In his February 2, 2022 column in the Palestinian daily Al-Ayyam, journalist 'Abd Al-Ghani Salameh contrasted the scientific breakthroughs taking place in the world today with the situation of the Arab and Muslim world, which he said is mired in backwardness, chaos and internal strife, stemming from an obsolete thinking and hostility towards the West. If this situation persists, he said, the Arab peoples may find themselves in danger of extinction.

'Abd Al-Ghani Salameh (Source: Hadfnews.ps)

The following are translated excerpts from his article:[1]

"Over the last two decades, scientists have made great strides in all areas. Some [of the developments] changed our lives completely, while others brought about a smaller change, but all of them had a significant impact on the future of humanity, laying the foundations for a completely new era and a historic turning point. Just as the steam engine launched the Industrial Revolution and the discovery of electricity led to the invention of countless apparatuses, the internet launched the era of the information and media revolution.

"The achievements of this [20-year] period, a very short time in the life of humanity, are even more important than the achievements of the previous eras. Their significance lies in their potential to bring change, just like the earlier inventions and discoveries

"The following is a summary of the most important achievements [of the last two decades]. The most significant, and also the most expensive, was the establishment of the European Organization for Nuclear Research, CERN, on the border between Switzerland and France, built through the most extensive international scientific cooperation since [the construction of] the international space station. [Housing] the world's largest particle accelerator, 27 km long, it is meant to provide a better understanding of the emergence of the cosmos by simulating the Big Bang

"In the realm of space [exploration], the giant James Webb Telescope was recently launched into orbit and will replace the Hubble Telescope. It is the fruit of 25 years of labor by scientists from NASA and the Canadian and European space agencies, and it is hoped to provide answers to many questions that have preoccupied humanity Scientists have also discovered the closest planet to earth that may be hospitable to life, although it is very far away, and a black hole has been photographed for the first time, in the center of a faraway galaxy. The Phoenix space probe landed on the surface of Mars and took detailed photos of the Red Planet while the Voyager I Space probe continues its journey to the edges of the cosmos

"The most important medical development, which will take biology to another level, is the complete mapping of the human genome, and the discovery of the molecular structure of human [DNA]. This breakthrough allowed the development of synthetic biology, and scientists have managed to create the first living organism using synthetic DNA Also in the field of medicine, American and Japanese scientists managed to clone human stem cells from skin cells, in a way that does not violate any ethical principles and ensures that the body will not reject them. Using these stem cells, they developed the first complete cure for diabetes. The first artificial heart was developed as well as well as a smart prosthetic hand that can be controlled by the mind.

"In the realm of technology, there were incredible breakthroughs in the area of carbon nanofibers, artificial intelligence and robotics; the 3D printer and Bluetooth technology were developed as well as smart surfaces, virtual keyboards, touch screens, smartphones, social media and audiovisual media. Ecommerce is thriving, and distributers like Amazon and Alibaba have emerged. Electric and hybrid cars, as well as self-driving cars, are being made, Google has mapped every part of the [planet] and all its road systems using GPS, and the G5 internet has arrived

"If we go into detail, we will find dozens of additional important inventions and discoveries. But more important is that we [Arabs] understand our situation compared to the world. Where do we stand, and where are we headed? How far can we go?... It is important to give some profound thought to our local reality and remember our [own] achievements in the last [20] years, [namely] the growing corruption of the Arab regimes, which triggered the Arab Spring revolutions that produced a reality no less corrupt. Throughout these years and before them, we have been mired in backwardness, chaos, civil war, bombings, terror, tribal and sectarian conflict and the reduplication of totalitarian regimes. This is due to the fact that we refuse to even acknowledge the problem and are unable to understand its essence, for we are trapped in an obsolete Salafi mentality and are hostile to the entire world, refusing to integrate in the [global] human culture. The truth, gentlemen, is that we Arabs and Muslims are isolated from the world and from reality, light years removed from the train of progress. True, many recent inventions and discoveries were produced by Arab scientists, but they were made in laboratories and research centers located in the 'infidel' West. If we stay on this course, we will be among the peoples in danger of extinction."

[1] Al-Ayyam (Palestinian Authority), February 2, 2022.

Follow this link:
Palestinian Journalist: The Arab And Muslim World Is Mired In Backwardness, Light Years Behind The World's Rapid Development - Middle East Media...

Skin Stem Cells Comments Off on Palestinian Journalist: The Arab And Muslim World Is Mired In Backwardness, Light Years Behind The World’s Rapid Development – Middle East Media… | June 30th, 2022

Retinol has been shown to increase collagen production, eradicating fine lines and wrinkles. Cop these top retinol eye creams right now.

This goes without saying dermatologists adore retinol.

The vitamin A derivative has been shown to increase collagen production, eradicating fine lines and wrinkles. When it comes to your eyes, however, a product created particularly for the delicate skin around the eyes is preferable to your normal retinol cream. So weve compiled a list of the top retinol eye creams you should be using right now.

Because it has the thinnest skin on the body, the under-eye region is extremely sensitive. According to experts, retinol in this region may be overly irritating and, if not used correctly, might potentially induce inflammation. If youre concerned about irritation, only apply the product in the evening. Retinols have traditionally been used at night because UV exposure can inactivate vitamin A derivatives, and retinols can make the skin more UV sensitive, according to dermatologists.

When used on a daily basis, retinol will tighten and smooth the skin beneath and around your eyes. The best part is that there are so many eye cream compositions available that there is no need to use a one-size-fits-all strategy. Instead, we discovered 8 retinol eye products, each of which addresses a distinct issue while leaving all skin types smooth, moisturised, and irritation-free.

Charlottes Magic Eye Rescue dramatically enhances elasticity and firmness with a cocktail of cell-energising winter daphne stem cell extract, rice and soy peptides, saccharide isomerate and free radical-fighting vitamins A, C and E all alongside a proprietary botanical eye contour complex that works to increase stretch, resilience and density for younger-looking eyes. Reparative and protective, this replenishing cream has an instant skin-smoothing and lifting effect ideal for disguising signs of a too-late night while the inclusion of moisturising coconut oil and shea butter helps to lock in precious moisture to restore skins bounce and softness.

Intensely nourishing, this luxurious Avocado Melt Retinol Eye Sleeping Mask is crammed with moisturising, age-defying and brightening ingredients to leave you looking bright eyed and bushy tailed in the morning. Rich in antioxidants including conditioning vitamins E and C, avocado oil and extract soothe and nourishe the delicate under-eye area while protecting it against harmful environmental aggressors like free radicals.

Other hard-working ingredients include niacinamide, which helps to strengthen the skins barrier while visibly improving the appearance of dullness, fine lines and wrinkles, along with caffeine-laced coffeeberry to reduce puffiness and dark circles. The star of the show? Encapsulated retinol, which helps to firm, smooth and plump fine lines and wrinkles without the harsher side effects often associated with retinol.

Vitamin A derivatives have been proven to work at the cellular level to brighten skin and stimulate collagen production. The INKEY List Retinol Eye Cream offers an alternative to traditionally irritating retinoids: a ground-breaking slow-release formula plus rich but lightweight oils so its gentle enough to use around the eyes. This night-time eye cream is formulated with Shea Butter to moisturise and soothe while also reducing the appearance of fine lines and wrinkles. Its an eye cream that actually works.

This quick-absorbing serum features the brands signature Phyto-Retinol Blend that targets signs of ageing around the eyes through three methods of firming skin, boosting hydration, and reducing the look of fine lines. Besides retinol, bakuchiol, rambutan, and ferulic acid also work their magic to smoothen out visible wrinkles.

A supercharged treatment for skin that shows signs of a cellular slow-down, this revitalising serum is jam-packed with instant and time-released retinol to rev your cells engines and rapidly minimise lines while recovering radiance. From firmness to furrows and texture to tone this breakthrough formula has a rapid impact; smoothing and softening wrinkles and boosting resilience, leaving your face looking less lined and youthfully dewy. Created to deliver results without retinols side-effects, this non-irritating elixir is great for all skin types

The Laneige Perfect Renew Youth Retinol Eye Cream penetrates deep into the delicate skin surface around your eyes. Its said to reduce deep and surface wrinkles of each skin layer in only a week by dimishing the number, depth, length and area of wrinkles with pure retinol. Five hyaluronic acids in different sizes work alongside to replenish moisture in the skin to densify the skin and boost 3firmness zones.

This silky, weightless eye cream improves the appearance of skin firmness, texture and elasticity and reduces the appearance of lines and wrinkles around the eye area. It firms with retinol and bioretinols, natural ingredients that mimic the effort of retinol but with less sensitivity. Hyaluronic acid increases hydration and helps smooth the appearance of skin.

Originally posted here:
Worried about your Under-Eyes? Here are the Top Retinol Eye Creams to Try - Prestige Online Thailand

Skin Stem Cells Comments Off on Worried about your Under-Eyes? Here are the Top Retinol Eye Creams to Try – Prestige Online Thailand | June 30th, 2022

Introduction

Spiradenoma is a rare type of adnexal tumors originating from the eccrine glands.1,2 The etiology remains unknown. This condition was first introduced by Kersting and Helwig in 1956.1 Its clinical features consist of skin-colored, erythematous, gray, or bluish2 nodules1 accompanied with pain.1,2 The lesions of spiradenoma are generally solitary,1 with the most common predilection being on the ventral part of the body,3 especially on the upper part of the trunk.1 Atypical clinical features of spiradenoma may occur as multiple lesions arranged in a linear or zosteriform arrangement.2,3 Spiradenoma can occur at any age,1 most commonly between 15 and 35 years old.2 There is no difference of incidence among genders.1,2 There are various therapeutic modalities for spiradenoma, including surgical excision, dermabrasion, electrodesiccation, cryosurgery, radiotherapy, and CO2 laser.2,4 However, the efficacy of some of these modalities has not been determined.4 In 2013, Gordon et al5 in the United States reported a case of spiradenoma treated using injection of triamcinolone acetonide (TA) 10 mg/mL with minimal improvement. Gottschalk et al6 administered TA 40 mg/mL in one case of adnexal tumor with a 75% reduction in lesion size. This study aims to report a rare case of giant spiradenoma which was treated by 10 mg/mL TA injection.

A 31-year-old man presented with giant painful skin-colored and erythematous nodules on his left eyelid and left temple (Figure 1A). The lesion first appeared 15 years prior to consultation as a skin-colored papule on the left eyelid which enlarged into a nodule after 5 years. New nodules appeared on his left temple around 5 years ago and grew larger one year prior. There was no other significant past medical or family history. Dermatological examination revealed firm, skin-colored nodules with smooth surface and well-defined boundaries, painful upon palpation, measuring 1.52.8 x 0.3 cm and 1.61.7 x 0.4 cm. We performed a punch biopsy on the left temple. The histopathological result revealed a tumor mass consisting of round to oval cells with hyperplastic, compact, and nodular characteristics. Some cells formed a tubular structure, and some appeared paler and larger. The cells had monomorphous nuclei with few inflammatory cells. There were no signs of malignancy (Figure 2A and B). The patient refused surgical therapy. Therefore, we performed intralesional injection of 10 mg/mL TA, consisting of five injections per visit. After four sessions of TA injections with one month interval, the lesions grew thinner and smaller and the pain disappeared (Figure 1B). There were no side effects reported.

Figure 1 (A) Clinical manifestations of spiradenoma in the form of skin-colored and erythematous nodules on the left eyelid and left temple before triamcinolone acetonide injection. (B) Spiradenoma lesions after triamcinolone acetonide injection.

Figure 2 Histopathological findings. (A) Red arrow shows one tumor mass. (B) Tumor mass consisted of round, oval cells showing hyperplastic, compact, and nodular characteristics. Some formed a tubular structure. Some cells appeared paler and larger.

Adnexal tumors are classified based on their differentiation in forming skin adnexal structures into eccrine, apocrine, follicular, and sebaceous gland tumors. They are further divided into benign and malignant types. Benign tumors of the eccrine glands include cylindroma, hidradenoma, syringoma, poroma, and spiradenoma.3 There was no report on the prevalence of spiradenoma worldwide. It is considered to be a very rare disease.1,2

The exact etiology and pathogenesis of spiradenoma are unknown. It is suspected that a defect in the tumor suppressor gene plays a role in this disease.2 Several recent hypotheses have been proposed regarding spiradenoma, including abnormal multipotent stem cells in the folliculosebaceous unit and trauma as a triggering factor.7

Spiradenoma is characterized by skin-colored, erythematous, gray, or bluish2,3 nodules1 accompanied by pain.1,2 The lesions are generally solitary,1 and are often found on the ventral part of the body,3 especially the trunk.1 Our case of spiradenoma manifested as painful skin-colored and erythematous nodules on the patients face. This is in accordance with the signs, symptoms, and predilection of spiradenoma.

Some tumors of the skin are difficult to diagnose clinically due to the lack of external characteristics that allow recognition through inspection alone. Several painful subcutaneous tumors which can be considered as differential diagnoses are spiradenoma, neuroma, glomus tumor, leiomyoma, angiolipoma, neurilemmoma, and dermatofibroma.8 Histopathological examination is therefore necessary to establish the diagnosis of spiradenoma.9 The histopathological features of spiradenoma include non-capsulated dermal neoplasms with single or multinodular nodules,10 consisting of basaloid cells, arranged in a tubular structure.3 There are two types of cells that can be found: small basaloid cells with hyperchromatic nuclei and little cytoplasm located at the edge of the nodules, and large basaloid cells with vesicular nuclei and pale cytoplasm located in the center of the nodules.3,8,10 Lymphocytes are also scattered throughout the tumor.3 The histopathological examination result in our case supported the diagnosis of spiradenoma.

Surgical excision is the current gold standard for treating spiradenoma with low recurrence rates. Meanwhile, the efficacy of several other therapeutic modalities has yet to be determined.4 Several investigators had studied other less invasive therapies for spiradenoma. In 2013, Gordon et al5 in the United States reported a case of spiradenoma treated using intralesional 10 mg/mL TA injection, but there was minimal improvement. Gottschalk et al6 treated a skin adnexal tumor with intralesional 40 mg/mL TA injection. A total of 1 mL of 40 mg/mL TA aqueous suspension was injected into a single 4 cm lesion. After one injection, the size of the tumor was reduced by 75%.6 Steroid use in this case aimed to reduce inflammation that can be associated with pain.5 Corticosteroids have anti-inflammatory, immunosuppressive, antiproliferative, and vasoconstrictive effects.11 The intralesional skin injection method was chosen to achieve a localized corticosteroid concentration in the lesion with less systemic absorption, thereby avoiding systemic side effects. The mechanism of how intradermal steroid affects the course of the disease remains unknown.12 Our patient was treated with intralesional 10 mg/mL TA injections due to refusal to undergo surgery. Improvement was observed after the fourth injection: the skin lesions became thinner and smaller. The pain also diminished.

Intralesional injection of TA can be a therapeutic option for spiradenoma patients who refuse surgical therapy. TA injection is easy to administer and showed good efficacy in spiradenoma case, although further research with a larger number of patients remains needed.

The publication of case images was included in the patients consent. Institutional approval to publish case details has been obtained.

The authors have obtained all appropriate patient consent forms. The patient signed a consent form for the publication of case details and images.

The authors would like to thank the entire staff of the Dermatology and Venereology Department, Faculty of Medicine, Universitas Padjadjaran Hasan Sadikin General Hospital Bandung, West Java Indonesia.

The authors report no conflicts of interest in this work.

1. Kanwaljeet S, Chatterjee T. Eccrine spiradenoma: a rare adnexal tumor. Indian J Cancer. 2017;54(4):695. doi:10.4103/ijc.IJC_301_17

2. Dhua S, Sekhar DR. A rare case of eccrine spiradenomatreatment and management. Eur J Plast Surg. 2016;39(2):143146. doi:10.1007/s00238-015-1103-4

3. Foreman RK, Duncan LM. Appendage tumors of the skin. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, editors. Fitzpatricks Dermatology. 9th ed. New York: McGraw-Hill; 2019:18201853.

4. Nath AK, Kumari R, Thappa DM. Eccrine spiradenoma with chondroid syringoma in Blaschkoid distribution. Indian J Dermatol Venereol Leprol. 2009;75(6):600. doi:10.4103/0378-6323.57723

5. Gordon S, Styron BT, Haggstrom A. Pediatric segmental eccrine spiradenomas: a case report and review of the literature. Pediatr Dermatol. 2013;30(6):e285e286. doi:10.1111/j.1525-1470.2012.01777.x

6. Gottschalk HR. Dermatological clinical conference scientific program for the 102nd annual session California medical association. Arch Dermatol. 1974;110(3):473479. doi:10.1001/archderm.1974.01630090095041

7. Englander L, Emer JJ, McClain D, Amin B, Turner RB. A rare case of multiple segmental eccrine spiradenomas. J Clin Aesthet Dermatol. 2011;4(4):38.

8. Naversen DN, Trask DM, Watson FH, Burket JM. Painful tumors of the skin: LEND AN EGG. J Am Acad Dermatol. 1993;28(2):290300. doi:10.1016/0190-9622(93)70039-V

9. Sharma A, Paricharak DG, Nigam JS, et al. Histopathological study of skin adnexal tumoursinstitutional study in South India. J Skin Cancer. 2014;2014:14. doi:10.1155/2014/543756

10. Weedon D. Tumors of cutaneous appendages. In: Weedons Skin Pathology. 3rd ed. Brisbane: Elsevier Inc; 2010:758807.

11. Kerscher M, Williams S, Lehmann P. Topical treatment with glucocorticoids. In: Ring J, Przybilla B, Ruzicka T, editors. Handbook of Atopic Eczema. 2nd ed. New YorkSpringer-Verlag Berlin Heidelberg; 2006:477491.

12. Firooz A, Tehranchia-Nia Z, Ahmed AR. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol. 1995;20(5):363370. doi:10.1111/j.1365-2230.1995.tb01351.x

Read the original:
Efficacy of Triamcinolone Acetonide Injection in Spiradenoma | IMCRJ - Dove Medical Press

Skin Stem Cells Comments Off on Efficacy of Triamcinolone Acetonide Injection in Spiradenoma | IMCRJ – Dove Medical Press | June 30th, 2022

For more in-depth learning, we recommend Different Approaches in our Patient Education program.

The challenges of gene and cell therapists can be divided into three broad categories based on disease, development of therapy, and funding.

Challenges based on the disease characteristics: Disease symptoms of most genetic diseases, such as Fabrys, hemophilia, cystic fibrosis, muscular dystrophy, Huntingtons, and lysosomal storage diseases are caused by distinct mutations in single genes. Other diseases with a hereditary predisposition, such as Parkinsons disease, Alzheimers disease, cancer, and dystonia may be caused by variations/mutations in several different genes combined with environmental causes. Note that there are many susceptible genes and additional mutations yet to be discovered. Gene replacement therapy for single gene defects is the most conceptually straightforward. However, even then the gene therapy agent may not equally reduce symptoms in patients with the same disease caused by different mutations, and even the samemutationcan be associated with different degrees of disease severity. Gene therapists often screen their patients to determine the type of mutation causing the disease before enrollment into a clinical trial.

The mutated gene may cause symptoms in more than one cell type. Cystic fibrosis, for example, affects lung cells and the digestive tract, so the gene therapy agent may need to replace the defective gene or compensate for its consequences in more than one tissue for maximum benefit. Alternatively, cell therapy can utilizestem cellswith the potential to mature into the multiple cell types to replace defective cells in different tissues.

In diseases like muscular dystrophy, for example, the high number of cells in muscles throughout the body that need to be corrected in order to substantially improve the symptoms makes delivery of genes and cells a challenging problem.

Some diseases, like cancer, are caused by mutations in multiple genes. Although different types of cancers have some common mutations, every tumor from a single type of cancer does not contain the same mutations. This phenomenon complicates the choice of a single gene therapy tactic and has led to the use of combination therapies and cell elimination strategies. For more information on gene and cell therapy strategies to treat cancer, please refer to the Cancer and Immunotherapy summary in the Disease Treatment section.

Disease models in animals do not completely mimic the human diseases and viralvectorsmay infect various species differently. The testing of vectors in animal models often resemble the responses obtained in humans, but the larger size of humans in comparison to rodents presents additional challenges in the efficiency of delivery and penetration of tissue.Gene therapy, cell therapy, and oligonucleotide-based therapy agents are often tested in larger animal models, including rabbit, dog, pig and nonhuman primate models. Testing human cell therapy in animal models is complicated by immune rejections. Furthermore, humans are a very heterogeneous population. Their immune responses to the vectors, altered cells, or cell therapy products may differ or be similar to results obtained in animal models.

Challenges in the development of gene and cell therapy agents: Scientific challenges include the development of gene therapy agents that express the gene in the relevant tissue at the appropriate level for the desired duration of time. There are a lot of issues in that once sentence, and while these issues are easy to state, each one requires extensive research to identify the best means of delivery, how to control sufficient levels or numbers of cells, and factors that influence duration of gene expression or cell survival. After the delivery modalities are determined, identification and engineering of a promoter and control elements (on/off switch and dimmer switch) that will produce the appropriate amount of protein in the target cell can be combined with the relevant gene. This gene cassette is engineered into a vector or introduced into thegenomeof a cell and the properties of the delivery vehicle are tested in different types of cells in tissue culture. Sometimes things go as planned and then studies can be moved onto examination in animal models. In most cases, the gene/cell therapy agent may need to be improved further by adding new control elements to obtain the desired responses in cells and animal models.

Furthermore, the response of the immune system needs to be considered based on the type of gene or cell therapy being undertaken. For example, in gene or cell therapy for cancer, one aim is to selectively boost the existing immune response to cancer cells. In contrast, to treat genetic diseases like hemophilia and cystic fibrosis the goal is for the therapeutic protein to be accepted as an addition to the patients immune system.

If the new gene is inserted into the patients cellularDNA, the intrinsic sequences surrounding the new gene can affect its expression and vice versa. Scientists are now examining short DNA segments that may insulate the new gene from surrounding control elements. Theoretically, these insulator sequences would also reduce the effect of vector control signals in the gene cassette on adjacent cellular genes. Studies are also focusing on means to target insertion of the new gene into safe areas of the genome, to avoid influence on surrounding genes and to reduce the risk of insertional mutagenesis.

Challenges of cell therapy include the harvesting of the appropriate cell populations and expansion or isolation of sufficient cells for one or multiple patients. Cell harvesting may require specific media to maintain the stem cells ability toself-renew and mature into the appropriate cells. Ideally extra cells are taken from the individual receiving therapy. Those additional cells can expand in culture and can be induced to becomepluripotent stem cells(iPS), thus allowing them to assume a wide variety of cell types and avoiding immune rejection by the patient. The long term benefit of stem cell administration requires that the cells be introduced into the correct target tissue and become established functioning cells within the tissue. Several approaches are being investigated to increase the number of stem cells that become established in the relevant tissue.

Another challenge is developing methods that allow manipulation of the stem cells outside the body while maintaining the ability of those cells to produce more cells that mature into the desired specialized cell type. They need to provide the correct number of specialized cells and maintain their normal control of growth and cell division, otherwise there is the risk that these new cells may grow into tumors.

Challenges in funding: In most fields, funding for basic or applied research for gene and cell therapy is available through the National Institutes of Health (NIH) and private foundations. These are usually sufficient to cover the preclinical studies that suggest a potential benefit from a particular gene and cell therapy. Moving into clinical trials remains a huge challenge as it requires additional funding for manufacturing of clinical grade reagents, formal toxicology studies in animals, preparation of extensive regulatory documents, and costs of clinical trials.Biotechnology companies and the NIH are trying to meet the demand for this large expenditure, but many promising therapies are slowed down by lack of funding for this critical next phase.

Read the original here:
Gene & Cell Therapy FAQs | ASGCT - American Society of Gene & Cell ...

IPS Cell Therapy Comments Off on Gene & Cell Therapy FAQs | ASGCT – American Society of Gene & Cell … | June 30th, 2022

Stem cell technology will transform medical practice. While stem cell research has already elucidated many basic disease mechanisms, the promise of stem cellbased therapies remains largely unrealized. In this review, we begin with an overview of different stem cell types. Next, we review the progress in using stem cells for regenerative therapy. Last, we discuss the risks associated with stem cellbased therapies.

There are three major types of stem cells as follows: adult stem cells (also called tissue-specific stem cells), embryonic stem (ES) cells, and induced pluripotent stem (iPS) cells.

A majority of adult stem cells are lineage-restricted cells that often reside within niches of their tissue of origin. Adult stem cells are characterized by their capacity for self-renewal and differentiation into tissue-specific cell types. Many adult tissues contain stem cells including skin, muscle, intestine, and bone marrow (Gan et al, 1997; Artlett et al, 1998; Matsuoka et al, 2001; Coulombel, 2004; Humphries et al, 2011). However, it remains unclear whether all adult organs contain stem cells. Adult stem cells are quiescent but can be induced to replicate and differentiate after tissue injury to replace cells that have died. The process by which this occurs is poorly understood. Importantly, adult stem cells are exquisitely tissue-specific in that they can only differentiate into the mature cell type of the organ within which they reside (Rinkevich et al, 2011).

Thus far, there are few accepted adult stem cellbased therapies. Hematopoietic stem cells (HSCs) can be used after myeloablation to repopulate the bone marrow in patients with hematologic disorders, potentially curing the underlying disorder (Meletis and Terpos, 2009; Terwey et al, 2009; Casper et al, 2010; Hill and Copelan, 2010; Hoff and Bruch-Gerharz, 2010; de Witte et al, 2010). HSCs are found most abundantly in the bone marrow, but can also be harvested at birth from umbilical cord blood (Broxmeyer et al, 1989). Similar to the HSCs harvested from bone marrow, cord blood stem cells are tissue-specific and can only be used to reconstitute the hematopoietic system (Forraz et al, 2002; McGuckin et al, 2003; McGuckin and Forraz, 2008). In addition to HSCs, limbal stem cells have been used for corneal replacement (Rama et al, 2010).

Mesenchymal stem cells (MSCs) are a subset of adult stem cells that may be particularly useful for stem cellbased therapies for three reasons. First, MSCs have been isolated from a variety of mesenchymal tissues, including bone marrow, muscle, circulating blood, blood vessels, and fat, thus making them abundant and readily available (Deans and Moseley, 2000; Zhang et al, 2009; Lue et al, 2010; Portmann-Lanz et al, 2010). Second, MSCs can differentiate into a wide array of cell types, including osteoblasts, chondrocytes, and adipocytes (Pittenger et al, 1999). This suggests that MSCs may have broader therapeutic applications compared to other adult stem cells. Third, MSCs exert potent paracrine effects enhancing the ability of injured tissue to repair itself. In fact, animal studies suggest that this may be the predominant mechanism by which MSCs promote tissue repair. The paracrine effects of MSC-based therapy have been shown to aid in angiogenic, antiapoptotic, and immunomodulatory processes. For instance, MSCs in culture secrete hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), and vascular endothelial growth factor (VEGF) (Nagaya et al, 2005). In a rat model of myocardial ischemia, injection of human bone marrow-derived stem cells upregulated cardiac expression of VEGF, HGF, bFGF, angiopoietin-1 and angiopoietin-2, and PDGF (Yoon et al, 2005). In swine, injection of bone marrow-derived mononuclear cells into ischemic myocardium was shown to increase the expression of VEGF, enhance angiogenesis, and improve cardiac performance (Tse et al, 2007). Bone marrow-derived stem cells have also been used in a number of small clinical trials with conflicting results. In the largest of these trials (REPAIR-AMI), 204 patients with acute myocardial infarction were randomized to receive bone marrow-derived progenitor cells vs placebo 37 days after reperfusion. After 4 months, the patients that were infused with stem cells showed improvement in left ventricular function compared to control patients. At 1 year, the combined endpoint of recurrent ischemia, revascularization, or death was decreased in the group treated with stem cells (Schachinger et al, 2006).

Embryonic stem cells are derived from the inner cell mass of the developing embryo during the blastocyst stage (Thomson et al, 1998). In contrast to adult stem cells, ES cells are pluripotent and can theoretically give rise to any cell type if exposed to the proper stimuli. Thus, ES cells possess a greater therapeutic potential than adult stem cells. However, four major obstacles exist to implementing ES cells therapeutically. First, directing ES cells to differentiate into a particular cell type has proven to be challenging. Second, ES cells can potentially transform into cancerous tissue. Third, after transplantation, immunological mismatch can occur resulting in host rejection. Fourth, harvesting cells from a potentially viable embryo raises ethical concerns. At the time of this publication, there are only two ongoing clinical trials utilizing human ES-derived cells. One trial is a safety study for the use of human ES-derived oligodendrocyte precursors in patients with paraplegia (Genron based in Menlo Park, California). The other is using human ES-derived retinal pigmented epithelial cells to treat blindness resulting from macular degeneration (Advanced Cell Technology, Santa Monica, CA, USA).

In stem cell research, the most exciting recent advancement has been the development of iPS cell technology. In 2006, the laboratory of Shinya Yamanaka at the Gladstone Institute was the first to reprogram adult mouse fibroblasts into an embryonic-like cell, or iPS cell, by overexpression of four transcription factors, Oct3/4, Sox2, c-Myc, and Klf4 under ES cell culture conditions (Takahashi and Yamanaka, 2006). Yamakana's pioneering work in cellular reprogramming using adult mouse cells set the foundation for the successful creation of iPS cells from adult human cells by both his team (Takahashi et al, 2007) and a group led by James Thomson at the University of Wisconsin (Yu et al, 2007). These initial proof of concept studies were expanded upon by leading scientists such as George Daley, who created the first library of disease-specific iPS cell lines (Park et al, 2008). These seminal discoveries in the cellular reprogramming of adult cells invigorated the stem cell field and created a niche for a new avenue of stem cell research based on iPS cells and their derivatives. Since the first publication on cellular reprogramming in 2006, there has been an exponential growth in the number of publications on iPS cells.

Similar to ES cells, iPS cells are pluripotent and, thus, have tremendous therapeutic potential. As of yet, there are no clinical trials using iPS cells. However, iPS cells are already powerful tools for modeling disease processes. Prior to iPS cell technology, in vitro cell culture disease models were limited to those cell types that could be harvested from the patient without harm usually dermal fibroblasts from skin biopsies. However, mature dermal fibroblasts alone cannot recapitulate complicated disease processes involving multiple cell types. Using iPS technology, dermal fibroblasts can be de-differentiated into iPS cells. Subsequently, the iPS cells can be directed to differentiate into the cell type most beneficial for modeling a particular disease process. Advances in the production of iPS cells have found that the earliest pluripotent stage of the derivation process can be eliminated under certain circumstances. For instance, dermal fibroblasts have been directly differentiated into dopaminergic neurons by viral co-transduction of forebrain transcriptional regulators (Brn2, Myt1l, Zic1, Olig2, and Ascl1) in the presence of media containing neuronal survival factors [brain-derived neurotrophic factor, neurotrophin-3 (NT3), and glial-conditioned media] (Qiang et al, 2011). Additionally, dermal fibroblasts have been directly differentiated into cardiomyocyte-like cells using the transcription factors Gata4, Mef2c, and Tb5 (Ieda et al, 2010). Regardless of the derivation process, once the cell type of interest is generated, the phenotype central to the disease process can be readily studied. In addition, compounds can be screened for therapeutic benefit and environmental toxins can be screened as potential contributors to the disease. Thus far, iPS cells have generated valuable in vitro models for many neurodegenerative (including Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis), hematologic (including Fanconi's anemia and dyskeratosis congenital), and cardiac disorders (most notably the long QT syndrome) (Park et al, 2008). iPS cells from patients with the long QT syndrome are particularly interesting as they may provide an excellent platform for rapidly screening drugs for a common, lethal side effect (Zwi et al, 2009; Malan et al, 2011; Tiscornia et al, 2011). The development of patient-specific iPS cells for in vitro disease modeling will determine the potential for these cells to differentiate into desired cell lineages, serve as models for investigating the mechanisms underlying disease pathophysiology, and serve as tools for future preclinical drug screening and toxicology studies.

Despite substantial improvements in therapy, cardiovascular disease remains the leading cause of death in the industrialized world. Therefore, there is a particular interest in cardiovascular regenerative therapies. The potential of diverse progenitor cells to repair damaged heart tissue includes replacement (tissue transplant), restoration (activation of resident cardiac progenitor cells, paracrine effects), and regeneration (stem cell engraftment forming new myocytes) (Codina et al, 2010). It is unclear whether the heart contains resident stem cells. However, experiments show that bone marrow mononuclear cells (BMCs) can repair myocardial damage, reduce left ventricular remodeling, and improve heart function by myocardial regeneration (Hakuno et al, 2002; Amado et al, 2005; Dai et al, 2005; Schneider et al, 2008). The regenerative capacity of human heart tissue was further supported by the detection of the renewal of human cardiomyocytes (1% annually at the age of 25) by analysis of carbon-14 integration into human cardiomyocyte DNA (Bergmann et al, 2009). It is not clear whether cardiomyocyte renewal is derived from resident adult stem cells, cardiomyocyte duplication, or homing of non-myocardial progenitor cells. Bone marrow cells home to the injured myocardium as shown by Y chromosome-positive BMCs in female recipients (Deb et al, 2003). On the basis of these promising results, clinical trials in patients with ischemic heart disease have been initiated primarily using bone marrow-derived cells. However, these small trials have shown controversial results. This is likely due to a lack of standardization for cell harvesting and delivery procedures. This highlights the need for a better understanding of the basic mechanisms underlying stem cell isolation and homing prior to clinical implementation.

Although stem cells have the capacity to differentiate into neurons, oligodendrocytes, and astrocytes, novel clinical stem cellbased therapies for central and peripheral nervous system diseases have yet to be realized. It is widely hoped that transplantation of stem cells will provide effective therapy for Parkinson's disease, Alzheimer's disease, Huntington's Disease, amyloid lateral sclerosis, spinal cord injury, and stroke. Several encouraging animal studies have shown that stem cells can rescue some degree of neurological function after injury (Daniela et al, 2007; Hu et al, 2010; Shimada and Spees, 2011). Currently, a number of clinical trials have been performed and are ongoing.

Dental stem cells could potentially repair damaged tooth tissues such as dentin, periodontal ligament, and dental pulp (Gronthos et al, 2002; Ohazama et al, 2004; Jo et al, 2007; Ikeda et al, 2009; Balic et al, 2010; Volponi et al, 2010). Moreover, as the behavior of dental stem cells is similar to MSCs, dental stem cells could also be used to facilitate the repair of non-dental tissues such as bone and nerves (Huang et al, 2009; Takahashi et al, 2010). Several populations of cells with stem cell properties have been isolated from different parts of the tooth. These include cells from the pulp of both exfoliated (children's) and adult teeth, the periodontal ligament that links the tooth root with the bone, the tips of developing roots, and the tissue that surrounds the unerupted tooth (dental follicle) (Bluteau et al, 2008). These cells probably share a common lineage from neural crest cells, and all have generic mesenchymal stem cell-like properties, including expression of marker genes and differentiation into mesenchymal cells in vitro and in vivo (Bluteau et al, 2008). different cell populations do, however, differ in certain aspects of their growth rate in culture, marker gene expression, and cell differentiation. However, the extent to which these differences can be attributed to tissue of origin, function, or culture conditions remains unclear.

There are several issues determining the long-term outcome of stem cellbased therapies, including improvements in the survival, engraftment, proliferation, and regeneration of transplanted cells. The genomic and epigenetic integrity of cell lines that have been manipulated in vitro prior to transplantation play a pivotal role in the survival and clinical benefit of stem cell therapy. Although stem cells possess extensive replicative capacity, immune rejection of donor cells by the host immune system post-transplantation is a primary concern (Negro et al, 2012). Recent studies have shown that the majority of donor cell death occurs in the first hours to days after transplantation, which limits the efficacy and therapeutic potential of stem cellbased therapies (Robey et al, 2008).

Although mouse and human ES cells have traditionally been classified as being immune privileged, a recent study used in vivo, whole-animal, live cell-tracing techniques to demonstrate that human ES cells are rapidly rejected following transplantation into immunocompetent mice (Swijnenburg et al, 2008). Treatment of ES cell-derived vascular progenitor cells with inter-feron (to upregulate major histocompatibility complex (MHC) class I expression) or in vivo ablation of natural killer (NK) cells led to enhanced progenitor cell survival after transplantation into a syngeneic murine ischemic hindlimb model. This suggests that MHC class I-dependent, NK cell-mediated elimination is a major determinant of graft survivability (Ma et al, 2010). Given the risk of rejection, it is likely that initial therapeutic attempts using either ES or iPS cells will require adjunctive immunosuppressive therapy. Immunosuppressive therapy, however, puts the patient at risk of infection as well as drug-specific adverse reactions. As such, determining the mechanisms regulating donor graft tolerance by the host will be crucial for advancing the clinical application of stem cellbased therapies.

An alternative strategy to avoid immune rejection could employ so-called gene editing. Using this technique, the stem cell genome is manipulated ex vivo to correct the underlying genetic defect prior to transplantation. Additionally, stem cell immunologic markers could be manipulated to evade the host immune response. Two recent papers offer alternative methods for gene editing. Soldner et al (2011) used zinc finger nuclease to correct the genetic defect in iPS cells from patients with Parkinson's disease because of a mutation in the -Synuclein (-SYN) gene. Liu et al (2011) used helper-dependent adenoviral vectors (HDAdV) to correct the mutation in the Lamin A (LMNA) gene in iPS cells derived from patients with HutchinsonGilford Progeria (HGP), a syndrome of premature aging. Cells from patients with HGP have dysmorphic nuclei and increased levels of progerin protein. The cellular phenotype is especially pronounced in mature, differentiated cells. Using highly efficient helper-dependent adenoviral vectors containing wild-type sequences, they were able to use homologous recombination to correct two different Lamin A mutations. After genetic correction, the diseased cellular phenotype was reversed even after differentiation into mature smooth muscle cells. In addition to the potential therapeutic benefit, gene editing could generate appropriate controls for in vitro studies.

Finally, there are multiple safety and toxicity concerns regarding the transplantation, engraftment, and long-term survival of stem cells. Donor stem cells that manage to escape immune rejection may later become oncogenic because of their unlimited capacity to replicate (Amariglio et al, 2009). Thus, ES and iPS cells may need to be directed into a more mature cell type prior to transplantation to minimize this risk. Additionally, generation of ES and iPS cells harboring an inducible kill-switch may prevent uncontrolled growth of these cells and/or their derivatives. In two ongoing human trials with ES cells, both companies have provided evidence from animal studies that these cells will not form teratomas. However, this issue has not been thoroughly examined, and enrolled patients will need to be monitored closely for this potentially lethal side effect.

In addition to the previously mentioned technical issues, the use of ES cells raises social and ethical concerns. In the past, these concerns have limited federal funding and thwarted the progress of this very important research. Because funding limitations may be reinstituted in the future, ES cell technology is being less aggressively pursued and young researchers are shying away from the field.

Read this article:
The benefits and risks of stem cell technology - PMC

IPS Cell Therapy Comments Off on The benefits and risks of stem cell technology – PMC | June 30th, 2022

The future of therapeutics for Parkinson disease (PD) appears to be bright, with the pipeline of clinical development featuring a vast number of investigational and varied approaches to treating the condition. This is notable because although levodopaa gold standard therapyhas provided many patients with relief from PD symptoms, there are still limitations to its abilities, and there are several needs that remain unaddressed.

In a presentation given by Rajesh Pahwa, MD, FANA, FAAN, on these emerging therapies at the2022 Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congressin Washington, DC, June 17-19, four specific therapies on the horizon were highlighted that might be able to address, at least in part, some of the shortcomings of the available options.1 Pahwa, the Laverne and Joyce Rider Professor of Neurology; chief, Parkinsons Disease and Movement Disorders Division; and director, Parkinsons Foundation Center of Excellence, University of Kansas Medical Center, shared that IPX-203, apomorphine subcutaneous infusion, continuous foslevodopa/foscarbidopa infusion (also known as ABBV-591), and continuous subcutaneous liquid levodopa/carbidopa (also known as ND0612) could all enter the market within the next couple years.

If I were to predict, I would say the next four of them would definitely be in the market in the next 3 to 4 years, Pahwa said. We have had levodopa which is the gold standard for the treatment of Parkinson disease. We have had different extended forms of levodopawe had the sustained release carbidopa-levodopa that came out 30 years ago. We had the extended-release capsules that came out, about 4 to 5 years ago now. The next generation, so to speak, is IPX-203.

He said that likely, the next therapy that will become available will be subcutaneous apomorphine infusion, closely followed by foslevodopa/foscarbidopa, and then IPX-203. The Neuroderm subcutaneous liquid levodopa [ND0612] will be another few years later. The rest of themwe do not know where they'll end up with phase 3 studies, he said.

The thing is, we still don't have that perfect carbidopa-levodopa where we can say OK, we have reached the stage that this is the best one out there. But every extended-release formulation, we have made some degree of improvement over the past. The extended-release capsules were better than the sustained release because we could get immediate action. And the same thing, I think, with IPX-203. We will, hopefully, have a better improvement than we saw with the previous one, he continued.

After running through the available clinical data on these therapies, Pahwa began to look further into the future of treatment. Touching briefly on the gene therapies that have been assessedmostly unsuccessfullyin PD, he then turned to stem cell-based therapies. Speaking to the hope that patients often carry when talking about the potential of stem cell approaches, he shared that this approach can often come with difficulties, and the progress has been slow.

READ MORE: The Importance of Treatment Nuance and Novel Options in Treating Parkinson Disease

We are very early in the journey of stem cell therapies. The challenges with Parkinson are multiple. You have to figure out the source of this stem cell, the quality of stem cell, age of the patient, stage of the patient, surgical techniques used, the need to use immunosuppression therapy or not use immunosuppression therapy, Pahwa explained. We are looking at a lot of challenges that we have not completely eliminated when we talk about stem cells. But like I said, every patient really feels that the stem cell is going to be an answer to their Parkinson's disease. The challenge is, as far as being a clinician is that Parkinson's is a progressive disorder that affects multiple areas in the brain. Using stem cell therapy, can we stop this progression? Can we actually slow down the disease or cure it? Or is it really going to only focus on dopaminergic replacement? And I think those are our challenges.

These challenges as well as the promises, he explained, can also be unique to each source of stem cells that is taken with this approach. For fetal ventral mesencephalic cells or embryonic stem cells, there are a few trials ongoingthe TRANSEURO (NCT01898390), STEM-PD (NCT02452723), and NYSTEM (NCT03119636), specificallyand there have been positives with these cells, including good long-term graft survival and their indefinite expandability. But they do carry ethical concerns and can be both unpredictable and limited in terms of their supply. Additionally, tissue rejection and tumorigenesis are possible risks.

Induced pluripotent stem cells are another approach in an ongoing trial at the Center for iPS Cell Research and Application, in Kyoto, Japan. These cells, similar to the aforementioned ones, also come with the benefit of indefinite expandability, and unlike the prior mentioned, have an easily accessible source and lack the need for immunosuppressive therapy. Although, they have a high operative cost, can be time consuming to develop, and require complex procedures.

The final option, neural progenitor cells, are also being assessed in two clinical trials (NCT03309514 and NCT01329926), and offer an easy expansion and differentiation protocol, as well as a large quantity source and multipotency. But, again, they carry risks such as low graft survivability and limited proliferation, and they require invasive tissue collection.

People are surprised that we are so slow with stem cells, Pahwa said. Seven years ago, I used to say, Oh, it's going to be 5 to 10 years, and everyone was led to believe that it was all the federal governments fault that we were going so slow. But really, it takes a long time, looking at the safety of it, because all you need is one patient who have a significant complication, and this is going to be put on the backburner for a long time.

Pahwa stressed the importance of being honest with patients about the progress being made in this area, given the significant interest from the general population in stem cell approaches. He warned about patients seeking out unapproved, unregulated treatment by either traveling out of the United States, or within.

What I tell my patients is don't spend the money because a lot of people out there [are selling this idea], not only if you're talking about going to a different country, even in the US, he said. I have a patient who was walking and doing well, who had stem cells injected in her spine, and could not walk after that. It is very likely she had, some form of fibrosing meningitis or something that that affected her gait significantly. Not only there is no efficacy data, there is no safety data. So, I strongly try to discourage my patients.

But the challenge is, people who are interested in stem cells, they often don't believe you, they want to go because the person who's doing the stem cells is doing a very good job selling this product for them. I don't know how to say we can stop this from happening, and that's why I always talk about how there are very few studies going on, Pahwa said.

Click here for more coverage of ATMRD 2022.

Go here to see the original:
The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies - Neurology Live

IPS Cell Therapy Comments Off on The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies – Neurology Live | June 20th, 2022